[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 70 of about 70
1. Handisurya A, Rieger A, Bago-Horvath Z, Schellenbacher C, Bankier A, Salat A, Stingl G, Kirnbauer R: Rapid progression of an anal Buschke-Lowenstein tumour into a metastasising squamous cell carcinoma in an HIV-infected patient. Sex Transm Infect; 2009 Aug;85(4):261-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid progression of an anal Buschke-Lowenstein tumour into a metastasising squamous cell carcinoma in an HIV-infected patient.
  • BACKGROUND: Buschke-Löwenstein tumour (BLT) of the anogenitalia is a locally invasive, destructively growing verrucous carcinoma that does not metastasise.
  • Histologically BLT resembles benign condylomata acuminata.
  • Nevertheless, the tumour grows relentlessly and may rarely progress into squamous cell cancer (SCC).
  • RESULTS: A human immunodeficiency virus (HIV)-infected immunosuppressed patient developed (peri)anal warts accompanied by recurrent abscesses and fistulae.
  • Six months later, the tumour had progressed into an ulcerated SCC that destroyed the rectum and perineum, with metastases to the inguinal lymph nodes.
  • Whereas highly active antiretroviral therapy (HAART) effectively suppressed HIV replication, radiochemotherapy plus anti-EGFR antibody did not halt tumour progression, and the patient died from tumour-cachexia.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / secondary. HIV Infections / complications. Immunocompromised Host
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / virology. Anti-HIV Agents / therapeutic use. Cachexia / etiology. Fatal Outcome. Groin. HIV Seropositivity / drug therapy. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness


2. Wietfeldt ED, Thiele J: Malignancies of the anal margin and perianal skin. Clin Colon Rectal Surg; 2009 May;22(2):127-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancies of the anal margin and perianal skin.
  • Malignancies of the anal margin and perianal skin are relatively uncommon lesions, comprising 3 to 4% of all anorectal malignancies.
  • Buschke-Lowenstein tumor, or giant condyloma acuminatum, is not always included because this lesion is technically benign, although it displays aggressive local invasive behavior that makes it difficult to manage.
  • Proper diagnosis requires a high index of suspicion on the part of the surgeon.
  • Innocent local irritations will resolve in a short time with appropriate therapy; those that persist must be biopsied for tissue diagnosis.
  • Invasion and metastasis are relatively rare in this group of neoplasms; perianal Paget's disease has the highest risk of associated underlying neoplasm.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2008 Dec;51(12):1842-5 [18584248.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2 Suppl):S36-7 [17637368.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):427-31; discussion 431-2 [17430376.001]
  • [Cites] Br J Dermatol. 2007 Jan;156(1):11-21 [17199561.001]
  • [Cites] Dermatol Surg. 2001 Jun;27(6):587-90 [11442599.001]
  • [Cites] Dis Colon Rectum. 1997 Oct;40(10):1187-94 [9336114.001]
  • [Cites] Br J Dermatol. 1995 Jun;132(6):970-2 [7662577.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • (PMID = 20436838.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780245
  • [Keywords] NOTNLM ; Anal margin cancer / diagnosis / local excision / radiation therapy / treatment options
  •  go-up   go-down


3. MacNeill KN, Riddell RH, Ghazarian D: Perianal apocrine adenocarcinoma arising in a benign apocrine adenoma; first case report and review of the literature. J Clin Pathol; 2005 Feb;58(2):217-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for apocrine adenoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perianal apocrine adenocarcinoma arising in a benign apocrine adenoma; first case report and review of the literature.
  • Benign apocrine lesions have been described in the anogenital region, although according to the World Health Organisation convincing examples of anal apocrine adenocarcinomas have not been published.
  • This report describes the case of an invasive apocrine adenocarcinoma arising in a benign adenoma in the perianal region of a 45 year old woman.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Sweat Gland / pathology. Anus Neoplasms / pathology. Apocrine Glands / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Immunohistochemistry / methods. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for apocrine adenocarcinoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1999 Nov;52(11):829-32 [10690173.001]
  • [Cites] J Am Acad Dermatol. 2001 Nov;45(5):755-9 [11606929.001]
  • [Cites] J Am Acad Dermatol. 1980 Apr;2(4):322-6 [7364989.001]
  • [Cites] Arch Dermatol. 1980 Sep;116(9):1051-3 [7416759.001]
  • [Cites] Am J Clin Pathol. 1962 Feb;37:182-95 [14472046.001]
  • [Cites] Cancer. 1993 Jan 15;71(2):375-81 [7678545.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):832-6 [8037297.001]
  • [Cites] Am J Clin Pathol. 1998 Jan;109(1):75-84 [9426521.001]
  • [Cites] Mod Pathol. 1999 Aug;12(8):786-93 [10463481.001]
  • [Cites] Arch Pathol Lab Med. 1991 Dec;115(12):1249-54 [1662944.001]
  • (PMID = 15677547.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 12
  • [Other-IDs] NLM/ PMC1770559
  •  go-up   go-down


Advertisement
4. Mukherjee S, Frolova N, Sadlonova A, Novak Z, Steg A, Page GP, Welch DR, Lobo-Ruppert SM, Ruppert JM, Johnson MR, Frost AR: Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther; 2006 Jun;5(6):674-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer.
  • Using real-time, quantitative PCR, laser capture microdissection, and immunohistochemistry, distinctive patterns of expression of the hedgehog pathway members patched 1 (PTCH1), smoothened, GLI1, GLI2 and the 3 hedgehog ligands were identified for epithelial cells and stromal fibroblasts in benign breast and breast cancer.
  • Hedgehog-mediated transcription, as indicated by a reporter of GLI-dependent promoter activity and by expression of GLI1 transcripts, was reduced by the hedgehog pathway inhibitor cyclopamine in both MDA-MB-435 cancer epithelial cells and MCF10AT epithelial cells, a cell line derived from benign breast.
  • However, cyclopamine reduced viability of cancer epithelial cell lines, including MDA-MB-435, but did not specifically affect fibroblasts or epithelial cells from benign breast, including MCF10AT.
  • These results demonstrate modulation of GLI-mediated transcription in both cancer and benign-derived epithelial cells by cyclopamine and sonic hedgehog, and further suggest that hedgehog signaling contributes to the survival of only the cancer epithelial cells.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 2002 Apr;17(2):623-37 [11962762.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6 [16488983.001]
  • [Cites] Genes Dev. 2002 Nov 1;16(21):2743-8 [12414725.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):923-8 [12615704.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):508-13 [12652302.001]
  • [Cites] J Endocrinol. 2003 Sep;178(3):467-78 [12967338.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 6;314(2):313-20 [14733907.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] Biochem J. 2004 Mar 1;378(Pt 2):353-62 [14611647.001]
  • [Cites] J Agric Food Chem. 2004 May 19;52(10):2832-9 [15137822.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3479-85 [15150101.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):831-7 [15170664.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2577-85 [15277480.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):165-81 [15300011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]
  • [Cites] Development. 2004 Oct;131(20):5009-19 [15371305.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Int J Mol Med. 2004 Nov;14(5):793-9 [15492847.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Science. 1997 May 2;276(5313):817-21 [9115210.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):711-3 [10505029.001]
  • [Cites] Mol Cancer. 2004 Oct 13;3:29 [15482598.001]
  • [Cites] Breast Cancer Res. 2005;7(1):R46-59 [15642169.001]
  • [Cites] Development. 1999 Nov;126(22):5181-93 [10529434.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):236-43 [10981877.001]
  • [Cites] Nature. 2001 Feb 1;409(6820):633-7 [11214324.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1320-6 [11245428.001]
  • [Cites] J Invest Dermatol. 2001 Mar;116(3):472-4 [11231326.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):97-104 [11322829.001]
  • [Cites] Dev Biol. 2001 Oct 1;238(1):133-44 [11783999.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):118-27 [11857395.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]
  • [Cites] Histol Histopathol. 2002 Apr;17(2):599-621 [11962761.001]
  • [Cites] Dev Biol. 2005 Apr 1;280(1):111-21 [15766752.001]
  • [Cites] Genomics. 2005 Apr;85(4):462-71 [15780749.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):306-17 [15803137.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Development. 2005 Jul;132(14):3267-79 [15983404.001]
  • [Cites] J Neurosci. 2005 Sep 7;25(36):8338-46 [16148242.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1698-705 [15905200.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):139-48 [16003737.001]
  • [Cites] Hum Mol Genet. 2005 Nov 15;14(22):3379-88 [16203740.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):107-15 [12241103.001]
  • (PMID = 16855373.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA091421; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / R01 CA087728; United States / NCI NIH HHS / CA / R03 CA105950
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Hedgehog Proteins; 0 / RNA, Neoplasm; 0 / SHH protein, human; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ NIHMS11622; NLM/ PMC1557635
  •  go-up   go-down


5. Karanikolas BD, Figueiredo ML, Wu L: Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Mol Cancer Res; 2009 Sep;7(9):1456-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line.
  • Although this correlation means EZH2 could prove valuable as a biomarker in clinical settings, the question remains whether EZH2 is actually responsible for the initiation of these more aggressive tumor types.
  • In this study, EZH2-mediated neoplastic transformation of the normal prostate epithelial cell line benign prostate hyperplasia 1 (BPH1) was confirmed by in vivo tumor growth and in vitro colony formation.

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Matrix Biol. 1999 Oct;18(5):455-67 [10601733.001]
  • [Cites] BJU Int. 2000 May;85(7):932-44 [10792179.001]
  • [Cites] Genes Dev. 2001 Feb 1;15(3):267-85 [11159908.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):551-7 [11208850.001]
  • [Cites] Curr Opin Genet Dev. 2001 Apr;11(2):175-81 [11250141.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):950-8 [11298590.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1074-80 [11498575.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8143-9 [11719443.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2830-5 [11880635.001]
  • [Cites] Nature. 2002 Oct 10;419(6907):624-9 [12374981.001]
  • [Cites] Cell. 2002 Oct 18;111(2):197-208 [12408864.001]
  • [Cites] Science. 2002 Nov 1;298(5595):1039-43 [12351676.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):473-85 [12492490.001]
  • [Cites] Cell. 2003 Mar 7;112(5):599-606 [12628181.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1981-9 [12702592.001]
  • [Cites] J Natl Cancer Inst. 2003 May 7;95(9):661-8 [12734317.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):459-65 [12778136.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7841-6 [12799464.001]
  • [Cites] Mol Biol Cell. 2003 Jul;14(7):2728-43 [12857860.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11 [14500907.001]
  • [Cites] EMBO J. 2003 Oct 15;22(20):5323-35 [14532106.001]
  • [Cites] J Cell Biochem. 2004 Jan 1;91(1):13-25 [14689577.001]
  • [Cites] Neoplasia. 2003 Nov-Dec;5(6):481-8 [14965441.001]
  • [Cites] Curr Opin Genet Dev. 2004 Apr;14(2):155-64 [15196462.001]
  • [Cites] Oncogene. 2004 Jun 17;23(28):4930-7 [15077161.001]
  • [Cites] Mol Cell. 2004 Jul 2;15(1):57-67 [15225548.001]
  • [Cites] Genes Dev. 2004 Jul 1;18(13):1592-605 [15231737.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5759-69 [15208672.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(3):148-54 [2544306.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4682-9 [2547513.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):1721-32 [7906858.001]
  • [Cites] Nucleic Acids Res. 1995 Feb 25;23(4):628-33 [7899083.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1995 Jan;31(1):14-24 [7535634.001]
  • [Cites] EMBO J. 1997 Jun 2;16(11):3219-32 [9214638.001]
  • [Cites] Mol Cell Biol. 1998 Jun;18(6):3586-95 [9584199.001]
  • [Cites] J Virol. 1998 Oct;72(10):8150-7 [9733856.001]
  • [Cites] J Virol. 1998 Nov;72(11):8463-71 [9765382.001]
  • [Cites] Anal Biochem. 1999 May 15;270(1):41-9 [10328763.001]
  • [Cites] Exp Gerontol. 1999 Apr;34(2):275-87 [10363793.001]
  • [Cites] J Biol Chem. 2005 Jan 14;280(2):1199-208 [15536069.001]
  • [Cites] DNA Cell Biol. 2005 Feb;24(2):117-25 [15699631.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 10;102(19):6942-7 [15860580.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):22437-44 [15817459.001]
  • [Cites] Oncogene. 2005 Sep 15;24(41):6269-80 [16007202.001]
  • [Cites] Science. 2005 Oct 14;310(5746):306-10 [16224021.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7465-74 [16288293.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):268-73 [16330673.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1168-74 [16489070.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):639-45 [16575874.001]
  • [Cites] Methods Enzymol. 2006;407:660-76 [16757360.001]
  • [Cites] J Biol Chem. 2006 Aug 25;281(34):24790-802 [16766534.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14122-7 [16959882.001]
  • [Cites] J Cell Physiol. 2007 Jan;210(1):183-91 [16998811.001]
  • [Cites] Genes Dev. 2007 Jan 1;21(1):49-54 [17210787.001]
  • [Cites] Nat Cell Biol. 2007 Mar;9(3):347-53 [17277772.001]
  • [Cites] Prostate. 2007 Apr 1;67(5):547-56 [17252556.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1261-74 [17604717.001]
  • [Cites] Mol Carcinog. 2008 Jun;47(6):466-77 [18058808.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7828-37 [18829538.001]
  • [Cites] Science. 2008 Dec 12;322(5908):1695-9 [19008416.001]
  • [Cites] J Cutan Pathol. 2007 Aug;34(8):597-600 [17640228.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2153-61 [17583576.001]
  • [Cites] Cancer Cell. 2007 Nov;12(5):419-31 [17996646.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10657-63 [18006806.001]
  • [Cites] Int J Cancer. 2008 Feb 1;122(3):595-602 [17943722.001]
  • [Cites] Prostate. 2008 Feb 15;68(3):255-63 [18095286.001]
  • [Cites] Dis Markers. 2008;24(3):157-65 [18334737.001]
  • (PMID = 19723877.001).
  • [ISSN] 1557-3125
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA092131-08; United States / NCI NIH HHS / CA / P50 CA092131; United States / NCI NIH HHS / CA / P30 CA016042; United States / NIAID NIH HHS / AI / P30 AI028697; United States / NCI NIH HHS / CA / R01 CA101904-07; United States / NCI NIH HHS / CA / R01 CA101904; United States / NCI NIH HHS / CA / CA101904-07
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Transcription Factors; 147336-22-9 / Green Fluorescent Proteins; EC 2.1.1.- / Protein Methyltransferases; EC 2.1.1.43 / EZH2 protein, human; EC 2.1.1.43 / Polycomb Repressive Complex 2; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ NIHMS159142; NLM/ PMC2794652
  •  go-up   go-down


6. Okada F, Shionoya H, Kobayashi M, Kobayashi T, Tazawa H, Onuma K, Iuchi Y, Matsubara N, Ijichi T, Dugas B, Hosokawa M: Prevention of inflammation-mediated acquisition of metastatic properties of benign mouse fibrosarcoma cells by administration of an orally available superoxide dismutase. Br J Cancer; 2006 Mar 27;94(6):854-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of inflammation-mediated acquisition of metastatic properties of benign mouse fibrosarcoma cells by administration of an orally available superoxide dismutase.
  • In the oxykine group, tumour incidence was lower (41%) than in the gliadin or saline group (83 and 79%, respectively).
  • When perfused in situ with nitroblue tetrazolium, an indicator of superoxide formation, the tumour masses from gliadin and saline groups displayed intense formazan deposition, whereas, those from oxykine group had less deposition.
  • Arising tumour cells in gliadin and saline groups acquired metastatic phenotype, but those in oxykine group showed reduced metastatic ability.
  • These results suggested that the orally active SOD derivative prevented tumour progression promoted by inflammation, which is thought to be through scavenging inflammatory cell-derived superoxide anion.
  • [MeSH-major] Fibrosarcoma / immunology. Fibrosarcoma / pathology. Inflammation. Neoplasm Metastasis / immunology. Superoxide Dismutase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1978 Sep;38(9):2759-62 [679181.001]
  • [Cites] FEBS J. 2005 Sep;272(17):4431-8 [16128812.001]
  • [Cites] N Engl J Med. 1980 Jul 3;303(1):27-34 [6246431.001]
  • [Cites] Exp Eye Res. 1981 Dec;33(6):651-61 [6797833.001]
  • [Cites] Gene Ther. 2001 Jan;8(2):149-56 [11313784.001]
  • [Cites] Gut. 2003 Feb;52(2):218-23 [12524403.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):424-32 [12538496.001]
  • [Cites] Redox Rep. 2002;7(6):357-68 [12625943.001]
  • [Cites] Nat Med. 2003 Jun;9(6):750-5 [12730689.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2221-32 [14633597.001]
  • [Cites] J Ethnopharmacol. 2004 Sep;94(1):67-75 [15261965.001]
  • [Cites] J Biol Chem. 1969 Nov 25;244(22):6049-55 [5389100.001]
  • [Cites] Anal Biochem. 1971 Nov;44(1):276-87 [4943714.001]
  • [Cites] J Clin Invest. 1973 Mar;52(3):741-4 [4346473.001]
  • [Cites] Cancer Res. 1982 Feb;42(2):609-17 [6275983.001]
  • [Cites] Int J Cancer. 1984 Jun 15;33(6):783-6 [6329968.001]
  • [Cites] Med Biol. 1984;62(5):285-9 [6530902.001]
  • [Cites] Biochem Biophys Res Commun. 1985 May 31;129(1):300-5 [2988549.001]
  • [Cites] J Biochem. 1986 May;99(5):1289-98 [3519601.001]
  • [Cites] Cancer Lett. 1986 Jul;32(1):7-13 [3017547.001]
  • [Cites] Int J Cancer. 1987 Mar 15;39(3):338-42 [2434441.001]
  • [Cites] J Biol Chem. 1988 May 15;263(14):6884-92 [3129432.001]
  • [Cites] Mol Cell Biochem. 1988 Dec;84(2):147-53 [3068520.001]
  • [Cites] Mol Cell Biochem. 1988 Dec;84(2):189-98 [3231222.001]
  • [Cites] Am J Pathol. 1989 Apr;134(4):787-96 [2705506.001]
  • [Cites] Free Radic Biol Med. 1989;6(4):379-84 [2540070.001]
  • [Cites] J Cell Physiol. 1989 May;139(2):370-6 [2715192.001]
  • [Cites] Science. 1989 May 26;244(4907):974-6 [2543070.001]
  • [Cites] Cancer Res. 1990 Apr 15;50(8):2538-42 [2317833.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):794-8 [1846317.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):939-43 [1988135.001]
  • [Cites] Cancer Lett. 1991 May 24;57(3):199-202 [2032208.001]
  • [Cites] J Biochem. 1991 Mar;109(3):477-85 [1880134.001]
  • [Cites] Free Radic Biol Med. 1992;12(4):281-6 [1315710.001]
  • [Cites] Adv Clin Chem. 1992;29:1-59 [1585847.001]
  • [Cites] Int J Cancer. 1992 May 28;51(3):476-80 [1592538.001]
  • [Cites] J Lab Clin Med. 1992 Jun;119(6):598-620 [1593209.001]
  • [Cites] Cancer Lett. 1992 Mar 15;62(3):211-5 [1596865.001]
  • [Cites] Br J Cancer. 1992 Oct;66(4):635-9 [1419599.001]
  • [Cites] Mol Carcinog. 1992;6(4):238-42 [1485915.001]
  • [Cites] Biofactors. 2005;23(2):85-95 [16179750.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):3113-7 [8464931.001]
  • [Cites] Mol Aspects Med. 1993;14(3):253-8 [8264340.001]
  • [Cites] Int J Cancer. 1994 Apr 15;57(2):287-92 [8157366.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4261-5 [8044768.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):233-8 [8054271.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12808-12 [7809125.001]
  • [Cites] Free Radic Biol Med. 1995 Apr;18(4):775-94 [7750801.001]
  • [Cites] Oncogene. 1995 May 18;10(10):1989-2000 [7761099.001]
  • [Cites] Cancer Res. 1995 Dec 15;55(24):6210-4 [8521415.001]
  • [Cites] Cancer Res. 1996 Jun 15;56(12):2864-71 [8665527.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3192-5 [8764104.001]
  • [Cites] Oncogene. 1997 Jan 30;14(4):481-90 [9053845.001]
  • [Cites] Science. 1997 Mar 14;275(5306):1649-52 [9054359.001]
  • [Cites] Histol Histopathol. 1997 Apr;12(2):525-35 [9151141.001]
  • [Cites] Cancer Immunol Immunother. 1998 Aug;46(6):338-44 [9756418.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):377-85 [10027302.001]
  • [Cites] J Biol Chem. 1999 Sep 3;274(36):25869-76 [10464329.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Free Radic Res. 2004 Sep;38(9):927-32 [15621710.001]
  • [Cites] Cancer Res. 1979 Apr;39(4):1141-9 [217531.001]
  • (PMID = 16508635.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.15.1.1 / Superoxide Dismutase
  • [Other-IDs] NLM/ PMC2361372
  •  go-up   go-down


7. Karaitianos IG, Archondakis SK, Korkolis D, Koundouris C, Xenitidis M, Daskalopoulou D, Tsigris C: The role of cytology in the diagnosis of benign and malignant anal lesions. Acta Chir Iugosl; 2006;53(2):39-42
MedlinePlus Health Information. consumer health - Anal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of cytology in the diagnosis of benign and malignant anal lesions.
  • Squamous cell carcinoma is a rather infrequent neoplasm of the gastrointestinal tract.
  • Squamous cell carcinoma is a slowly and locally growing neoplasm which metastasizes in advanced stages.
  • Its diagnosis must be accomplished by the least traumatic examinations possible.
  • In 89 of them cytological material from ulcerated positions of the anal region was examined.
  • In the rest 27 cytological material was obtained by fine needle aspiration of subcutaneous or submucosal anal lesions.
  • Cytological evaluation revealed 29 cases of normal anal epithelium, 13 granulomas, 12 cases of HPV infection, 28 anal squamous intraepithelial lesions (ASIL), 17 post radiation injuri-es of the anal mucosa and 17 carcinomas.
  • Histological examination followed the initial cytological diagnosis in 75 cases.
  • It is well accepted by the patients and of paramount clinical utility for the initial diagnostic assessment, the long-term follow up after treatment of anal cancer patients.
  • It is also valuable for the differential diagnosis among benign, premalignant and malignant anal lesions.
  • [MeSH-major] Anus Diseases / diagnosis. Anus Neoplasms / diagnosis. Biopsy, Needle
  • [MeSH-minor] Adult. Carcinoma, Squamous Cell / diagnosis. Cytodiagnosis. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139883.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


8. Christensen AF, Nyhuus B, Nielsen MB: Interobserver and intraobserver variation of two-dimensional and three-dimensional anal endosonography in the evaluation of recurrent anal cancer. Dis Colon Rectum; 2009 Mar;52(3):484-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interobserver and intraobserver variation of two-dimensional and three-dimensional anal endosonography in the evaluation of recurrent anal cancer.
  • PURPOSE: This study was designed to evaluate the interobserver and intraobserver agreement of two-dimensional (2-D) and three-dimensional (3-D) anal endosonography for the detection of local recurrence anal carcinoma.
  • METHODS: Thirty-six patients were treated for anal carcinoma, and seven had recurrent disease.
  • The observers scored each examination according to the following scale regarding presence of local recurrence: 1 = no finding/benign findings; 2 = properly benign findings; 3 = suspicious findings/malignant findings.
  • CONCLUSIONS: Three-dimensional endosonography proved to have significantly better interobserver and intraobserver agreement than 2-D endosonography concerning detection of recurrent anal cancer.
  • [MeSH-major] Anus Neoplasms / ultrasonography. Endosonography. Neoplasm Recurrence, Local / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / ultrasonography. Female. Humans. Imaging, Three-Dimensional. Male. Middle Aged. Observer Variation. Retrospective Studies

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19333050.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Christensen AF, Nielsen MB, Svendsen LB, Engelholm SA: Three-dimensional anal endosonography may improve detection of recurrent anal cancer. Dis Colon Rectum; 2006 Oct;49(10):1527-32
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional anal endosonography may improve detection of recurrent anal cancer.
  • PURPOSE: In our center since 2001, follow-up examination has included three-dimensional endosonography in all patients with suspicion of local recurrence of anal cancer.
  • METHODS: This prospective study included 38 consecutive patients who have had anal carcinoma and were investigated using three-dimensional endosonography in combination with anoscopy and digital rectal examination at Rigshospitalet from July 2001 to January 2005 under suspicion of local recurrence.
  • The observers scored each examination according to a five-point scale in which a score from 1 to 3 was regarded as benign endosonographic findings and a score from 4 to 5 was regarded as malignant endosonographic findings.
  • The endosonographic diagnosis for each examination was compared with histologic evaluation or when no biopsy had been taken with a follow-up period of at least six months.
  • CONCLUSIONS: This study indicates that three-dimensional endosonography surpasses two-dimensional endosonography in the evaluation of patients with suspicion of local recurrence of anal cancer especially in combination with anoscopy and digital rectal examination.
  • [MeSH-major] Anal Canal / ultrasonography. Anus Neoplasms / ultrasonography. Endosonography / methods. Imaging, Three-Dimensional. Neoplasm Recurrence, Local / ultrasonography

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988854.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Bernard JE, Butler MO, Sandweiss L, Weidner N: Anal intraepithelial neoplasia: correlation of grade with p16INK4a immunohistochemistry and HPV in situ hybridization. Appl Immunohistochem Mol Morphol; 2008 May;16(3):215-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal intraepithelial neoplasia: correlation of grade with p16INK4a immunohistochemistry and HPV in situ hybridization.
  • Accurate diagnosis and grading of anal intraepithelial neoplasia (AIN) can be problematic, especially in separating AIN from anal transitional-zone epithelium.
  • To investigate if p16 would help in more accurately diagnosing and grading AIN, particularly when attempting to distinguish benign transitional-zone epithelium from high-grade AIN, we separately assessed these stains in a blinded manner on a large number of consecutive anal biopsies and anal tissues and correlated the findings with the diagnosis and grade of AIN.
  • One hundred thirty-three consecutive anal tissue specimens, from 128 patients were studied.
  • One hundred and eight were anal biopsies and 25 were hemorrhoidectomy specimens.
  • We conclude that the correlation between AIN and p16 and HPV is strong enough to be quite useful in distinguishing true AIN from benign mimics, such as benign transitional-zone epithelium.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301250.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA Probes, HPV
  •  go-up   go-down


11. Emms SG: Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy. Aust Vet J; 2005 Jun;83(6):340-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy.
  • A retrospective study of anal sac tumours without pulmonary metastases, from the author's clinical records for the period July 1989 to July 2002, was conducted to establish the response to treatment with surgery and melphalan chemotherapy.
  • Of 21 dogs with tumours of the anal sacs 19 had apocrine gland adenocarcinomas of anal sac origin, one had a benign papillary cystadenoma and another had a malignant melanoma.
  • Two of the 19 dogs had bilateral anal sac adenocarcinomas.
  • Ten of the 19 dogs with apocrine gland adenocarcinomas of anal sac origin had sublumbar lymphadenopathy.
  • Fourteen dogs with apocrine gland adenocarcinomas of anal sac origin were treated by surgical cytoreduction and chemotherapy with melphalan.
  • Cytoreduction was by local excision of the anal sac in all 14 dogs and concurrent removal of the sublumbar retroperitoneal lymph nodes in the seven dogs with regional lymph node metastases.
  • The median survival time of dogs with sublumbar nodal metastasis was 20 months and for dogs with tumour localised to the anal sac the median survival time was 29.3 months.
  • This study suggests there is a role for melphalan in the treatment of dogs with anal sac adenocarcinoma when combined with cytoreductive surgery, with treatment survival times and the local recurrence rate of the primary tumour comparing favourably with previously published treatment regimes.
  • [MeSH-major] Anal Gland Neoplasms / epidemiology. Anal Sacs. Dog Diseases / epidemiology
  • [MeSH-minor] Adenocarcinoma / veterinary. Animals. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Cystadenoma, Papillary / veterinary. Dogs. Female. Male. Melanoma / veterinary. Neoplasm Metastasis. Records as Topic / veterinary. Retrospective Studies. Survival Analysis. Victoria / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986909.001).
  • [ISSN] 0005-0423
  • [Journal-full-title] Australian veterinary journal
  • [ISO-abbreviation] Aust. Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


12. Krishna CM, Sockalingum GD, Bhat RA, Venteo L, Kushtagi P, Pluot M, Manfait M: FTIR and Raman microspectroscopy of normal, benign, and malignant formalin-fixed ovarian tissues. Anal Bioanal Chem; 2007 Mar;387(5):1649-56
Hazardous Substances Data Bank. FORMALDEHYDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FTIR and Raman microspectroscopy of normal, benign, and malignant formalin-fixed ovarian tissues.
  • FTIR and Raman spectroscopic studies of formalin-fixed normal, benign, and malignant ovarian tissues have been undertaken in order to investigate and attempt to understand the underlying biochemical changes associated with the disease, and to explore the feasibility of discriminating between these different tissue types.
  • Among the pathological tissues studied, spectra from benign tissues seem to contain more proteins and less DNA and lipids compared to malignant tissue spectra.
  • FTIR and Raman spectra of both normal and benign tissues showed more similarities than those of malignant tissues.
  • Cluster analysis of first-derivative Raman spectra in the 700-1700 cm(-1) range gave two clear groups, one corresponding to malignant and the other to normal+benign tissues.
  • At a lower heterogeneity level, the normal+benign cluster gave three nonoverlapping subclusters, one corresponding to normal and two for benign tissues.
  • Cluster analysis of second-derivative FTIR spectra in the combined spectral regions of 1540-1680 and 1720-1780 cm(-1) resulted into two clear clusters corresponding to malignant and normal+benign tissues.
  • The cluster corresponding to normal+benign tissues produced nonoverlapping subclusters for normal and benign tissues at a lower heterogeneity level.
  • The findings of this study demonstrate the feasibility of Raman and FTIR microspectroscopic discrimination of formalin-fixed normal, benign, and malignant ovarian tissues.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasm Proteins / analysis. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Spectroscopy, Fourier Transform Infrared / methods. Spectrum Analysis, Raman / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043798.001).
  • [ISSN] 1618-2642
  • [Journal-full-title] Analytical and bioanalytical chemistry
  • [ISO-abbreviation] Anal Bioanal Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fixatives; 0 / Neoplasm Proteins; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


13. Borzomati D, Valeri S, Ripetti V, Vincenzi B, Rabitti C, Persichetti P, Valentini V, Trodella L, Caricato M, Coppola R: Persisting perianal ulcer after radiotherapy for anal cancer: recurrence of disease or late radiation-related complication? Hepatogastroenterology; 2005 May-Jun;52(63):780-4
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persisting perianal ulcer after radiotherapy for anal cancer: recurrence of disease or late radiation-related complication?
  • We report the case of a 47-year-old HIV-negative male affected by a perianal ulcer which occurred after chemoradiation delivered for anal cancer.
  • Uncontrollable pain and anal stenosis were also present; abdominoperineal resection with a large excision of perianal tissues and reconstruction with bilateral musculocutaneous gracilis flaps was therefore performed.
  • Histology did not confirm tumor recurrence.
  • The introduction of radiotherapy and concomitant chemotherapy has revolutionized the treatment of anal cancer, avoiding demolitive surgery in a large subset of patients.
  • Radionecrosis is an uncommon but potentially devastating event occurring in up to 10% of patients undergoing radiotherapy for anal cancer.
  • It causes clinical (pain, anal stenosis, mucositis and diarrhea) and diagnostic problems (recurrence vs. benign post-attinic lesion).
  • [MeSH-major] Anus Neoplasms / radiotherapy. Neoplasm Recurrence, Local / diagnosis. Perineum / radiation effects. Radiodermatitis / diagnosis. Ulcer / diagnosis
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / surgery. Biopsy. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Surgical Flaps

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966204.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


14. Lanteri R, Aliotta I, Racalbuto A, Licata A: Anal GIST in older old patient: a case report. G Chir; 2005 Apr;26(4):135-7
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal GIST in older old patient: a case report.
  • It is generally difficult to determine if they are to be considered as a benign or malignant neoplastic disease.
  • We present the case of a patient with recurrence of anal GIST who was examined 8 years after the first treatment.
  • During rectal exploration we found a mass spreading inside the lumen 3 cm from the anal verge.
  • Colonoscopy showed that the tumour, which was 7 x 5 cm in size, was inside the wall with normal mucosa.
  • Histological examination confirmed that the tumour was a GIST This case provides the basis for a discussion about characteristics and the evolution of this group of pathologies.
  • [MeSH-major] Anus Neoplasms / surgery. Gastrointestinal Stromal Tumors / surgery. Neoplasm Recurrence, Local
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16035248.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


15. Whitehouse PA, Tilney HS, Armitage JN, Simson JN: Transanal endoscopic microsurgery: risk factors for local recurrence of benign rectal adenomas. Colorectal Dis; 2006 Nov;8(9):795-9
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery: risk factors for local recurrence of benign rectal adenomas.
  • OBJECTIVE: Transanal endoscopic microsurgery (TEM) is a minimally invasive technique for excision of selected benign and malignant rectal neoplasms.
  • It is considered a safe and effective treatment but recurrence rates of 1-13% are reported for benign lesions.
  • The aim of this study was to assess risk factors for local recurrence of benign rectal lesions and to evaluate mortality and morbidity following TEM.
  • METHOD: Data were prospectively collected from all patients undergoing TEM for benign adenomas from January 1998 to March 2005.
  • CONCLUSION: TEM is a safe and effective treatment for benign rectal adenomas.
  • [MeSH-major] Adenoma / surgery. Endoscopy / methods. Microsurgery / methods. Neoplasm Recurrence, Local. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Follow-Up Studies. Humans. Middle Aged. Morbidity. Prospective Studies. Recovery of Function. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Colorectal Dis. 2006 Nov;8(9):731-2 [17032317.001]
  • (PMID = 17032328.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Guillem JG, Chessin DB, Jeong SY, Kim W, Fogarty JM: Contemporary applications of transanal endoscopic microsurgery: technical innovations and limitations. Clin Colorectal Cancer; 2005 Nov;5(4):268-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Transanal endoscopic microsurgery (TEM) is a minimally invasive procedure used to transanally excise select benign and malignant tumors of the rectum.
  • In addition, a PubMed literature search was performed with use of the key words "transanal endoscopic microsurgery," "TEM," "rectal tumor," and "rectal cancer."
  • Median tumor location was 9 cm from the anal verge (range, 3-15 cm).
  • Reasons for inability to complete TEM included narrow rectal lumen or contour of bony pelvis prohibiting passage of the operating proctoscope into the upper rectum and inability to maintain the proctoscope in the rectal lumen with carbon dioxide insufflation because of the distal location of the tumor.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Carcinoid Tumor / surgery. Colonoscopy / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Female. Humans. Male. Microsurgery. Middle Aged. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16356304.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Fatela-Cantillo D, Fernández-Suárez A, Menéndez V, Galán JA, Filella X: Low utility of CYFRA 21-1 serum levels for diagnosis and follow-up in bladder cancer patients. J Clin Lab Anal; 2005;19(4):167-71
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low utility of CYFRA 21-1 serum levels for diagnosis and follow-up in bladder cancer patients.
  • We evaluated serum levels of soluble fragments of cytokeratin 19 (CYFRA 21-1) by immunoassay (ES-700; Roche Diagnostics, Mannheim, Germany) to assess its usefulness in the diagnosis and follow-up of bladder cancer.
  • The study included 39 patients with a diagnosis of transitional cell carcinoma (group 1) and 190 patients (group 2) with no evidence of tumor.
  • In group 2, 180 patients had a history of bladder cancer, and 10 had benign prostatic hyperplasia.
  • However, CYFRA 21-1 levels did not significantly differ between the patients with benign prostatic hyperplasia and those with bladder cancer (P=0.274).
  • [MeSH-major] Antigens, Neoplasm / blood. Keratins / blood. Urinary Bladder Neoplasms / blood. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Female. Follow-Up Studies. Humans. Keratin-19. Male. Middle Aged

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16025482.001).
  • [ISSN] 0887-8013
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / antigen CYFRA21.1; 68238-35-7 / Keratins
  •  go-up   go-down


18. Garbar C, Mascaux C, Wespes E: Expression of MUC1 and sialyl-Tn in benign prostatic glands, high-grade prostate intraepithelial neoplasia and malignant prostatic glands: a preliminary study. Anal Quant Cytol Histol; 2008 Apr;30(2):71-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MUC1 and sialyl-Tn in benign prostatic glands, high-grade prostate intraepithelial neoplasia and malignant prostatic glands: a preliminary study.
  • STUDY DESIGN: One sample histologic paraffin block of 24 radical prostatectomies was selected for presence of both benign and malignant glands; 17 samples also included PIN.
  • RESULTS: MUC1 immunostaining was more often positive for neoplastic cells, progressively from benign (4.7+/-5.3%) to PIN (27.1+/-19.7%) and malignant glands (34.5+/-28.4%).
  • Both antibodies showed a statistical difference between benign glands and PIN or malignant glands but not between PIN and malignant.
  • CONCLUSION: MUC1 and sTn were expressed more intensely in PIN and malignant prostate glands than in benign glands. sTn seemed more specific in favor of cell malignancy.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18561742.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Sialomucins
  •  go-up   go-down


19. Kim JY, Lee YC, Kim C: Direct inhibition of Pumilo activity by Bam and Bgcn in Drosophila germ line stem cell differentiation. J Biol Chem; 2010 Feb 12;285(7):4741-6
SciCrunch. The Antibody Registry: Reagent: Antibodies .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The RNA-binding translational repressor Pumilio (Pum) in conjunction with Nanos (Nos) is required for self-renewal, whereas Bam (bag-of-marbles) and Bgcn (benign gonial cell neoplasm) promote differentiation of germ line stem cells in the Drosophila ovary.
  • Genetic analysis suggests that Bam and Bgcn antagonize Pum/Nos function to promote differentiation; however, the molecular basis of this epistatic relationship is currently unknown.
  • These studies suggest that, in cystoblasts, Bam and Bgcn may directly inhibit Pum/Nos activity to promote differentiation of germ line stem cells.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • FlyBase. FlyBase .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2704-12 [10541556.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jul 14;106(28):11623-8 [19556547.001]
  • [Cites] Development. 2000 Dec;127(23):5225-32 [11060247.001]
  • [Cites] Science. 2002 Jun 7;296(5574):1855-7 [12052957.001]
  • [Cites] Nat Rev Genet. 2002 Dec;3(12):931-40 [12459723.001]
  • [Cites] Curr Biol. 2003 Oct 14;13(20):1786-91 [14561403.001]
  • [Cites] Development. 2003 Dec;130(26):6625-34 [14660550.001]
  • [Cites] Development. 2004 Mar;131(6):1353-64 [14973291.001]
  • [Cites] Science. 2004 Mar 26;303(5666):2016-9 [14976263.001]
  • [Cites] Curr Biol. 2004 Jun 8;14(11):981-6 [15182671.001]
  • [Cites] J Bacteriol. 1983 Jan;153(1):163-8 [6336730.001]
  • [Cites] Anal Biochem. 1988 Jun;171(2):404-8 [3407940.001]
  • [Cites] Genetics. 1989 May;122(1):19-27 [2659436.001]
  • [Cites] Genes Dev. 1990 Dec;4(12B):2242-51 [2279698.001]
  • [Cites] Cell. 1991 Nov 29;67(5):955-67 [1720354.001]
  • [Cites] Development. 1992 Jan;114(1):221-32 [1576962.001]
  • [Cites] Cell. 1993 Nov 19;75(4):791-803 [8242750.001]
  • [Cites] Dev Dyn. 1994 Feb;199(2):103-15 [7515724.001]
  • [Cites] Cell. 1995 Mar 10;80(5):747-56 [7889568.001]
  • [Cites] Development. 1995 Sep;121(9):2937-47 [7555720.001]
  • [Cites] Development. 1997 Jun;124(12):2463-76 [9199372.001]
  • [Cites] Development. 1997 Sep;124(18):3651-62 [9342057.001]
  • [Cites] RNA. 1997 Dec;3(12):1421-33 [9404893.001]
  • [Cites] Development. 1998 Feb;125(4):679-90 [9435288.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1997;62:25-34 [9598333.001]
  • [Cites] Mol Cell. 1998 May;1(6):863-72 [9660969.001]
  • [Cites] Cell. 1998 Jul 24;94(2):251-60 [9695953.001]
  • [Cites] Dev Biol. 1999 Aug 15;212(2):405-13 [10433830.001]
  • [Cites] Genetics. 1999 Sep;153(1):235-50 [10471709.001]
  • [Cites] J Biol Chem. 1999 Oct 1;274(40):28491-6 [10497212.001]
  • [Cites] Curr Biol. 2005 Jan 26;15(2):171-8 [15668175.001]
  • [Cites] Curr Biol. 2005 Jan 26;15(2):179-84 [15668176.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jun;7(6):449-56 [16625152.001]
  • [Cites] Cell Res. 2007 Jan;17(1):15-25 [17199109.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1925-30 [18272501.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9304-9 [19470484.001]
  • [Cites] Genetics. 2000 Aug;155(4):1809-19 [10924476.001]
  • (PMID = 20018853.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drosophila Proteins; 0 / RNA-Binding Proteins; 0 / bam protein, Drosophila; 0 / pumilio protein, Drosophila; EC 3.6.4.- / DNA Helicases; EC 3.6.4.13 / bgcn protein, Drosophila
  • [Other-IDs] NLM/ PMC2836079
  •  go-up   go-down


20. Ooi BS, Quah HM, Fu CW, Eu KW: Laparoscopic high anterior resection with natural orifice specimen extraction (NOSE) for early rectal cancer. Tech Coloproctol; 2009 Mar;13(1):61-4
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The upper rectum distal to the tumour and proximal colon was transected with a laparoscopic stapler.
  • The patient, a 51-year-old male (BMI 18.6 kg/m(2)) with a 2.5-cm, early-stage posterior rectal cancer 12 cm from the anal verge, underwent the above-described procedure.
  • This procedure may be applicable to benign tumours and early colorectal cancer, and serves as an intermediate step between laparoscopic and natural orifice surgery.
  • [MeSH-minor] Anastomosis, Surgical. Colonoscopy. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19288243.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


21. Li X, Placencio V, Iturregui JM, Uwamariya C, Sharif-Afshar AR, Koyama T, Hayward SW, Bhowmick NA: Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis. Oncogene; 2008 Nov 27;27(56):7118-30
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.
  • In mice, the conditional stromal knockout of the TGF-beta type II receptor expression (Tgfbr2(fspKO)) resulted in the development of prostatic intraepithelial neoplasia and progression to adenocarcinoma within 7 months.
  • Clinically, we observed a loss of TGF-beta receptor type II expression in 69% of human prostate cancer-associated stroma, compared to 15% of stroma associated with benign tissues (n=140, P-value <0.0001).

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Jan 1;67(1):75-84 [17210685.001]
  • [Cites] Curr Opin Genet Dev. 2005 Feb;15(1):97-101 [15661539.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1305-13 [17415413.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4769-76 [17699854.001]
  • [Cites] Carcinogenesis. 2007 Dec;28(12):2467-75 [17690110.001]
  • [Cites] Anal Quant Cytol Histol. 2000 Feb;22(1):1-10 [10696454.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):230-5 [10861498.001]
  • [Cites] Genes Dev. 2000 Sep 15;14(18):2314-29 [10995388.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6008-17 [11085521.001]
  • [Cites] J Cell Physiol. 2001 Feb;186(2):153-68 [11169452.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8135-42 [11719442.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2679-94 [11965541.001]
  • [Cites] J Cell Biochem. 2002;86(4):665-77 [12210733.001]
  • [Cites] Cell. 2003 Jun 13;113(6):685-700 [12809600.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8621-3 [12861075.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):223-38 [14522256.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):491-8 [14760070.001]
  • [Cites] Science. 2004 Feb 6;303(5659):848-51 [14764882.001]
  • [Cites] Cancer. 2004 Sep 15;101(6):1345-56 [15316903.001]
  • [Cites] Development. 2004 Oct;131(20):4955-64 [15371309.001]
  • [Cites] J Urol. 1982 Oct;128(4):858-61 [7143620.001]
  • [Cites] Cell. 1982 Nov;31(1):99-109 [6297757.001]
  • [Cites] Nature. 1984 Jan 12-18;307(5947):131-6 [6318122.001]
  • [Cites] Endocrinology. 1990 Mar;126(3):1343-54 [2307108.001]
  • [Cites] In Vitro Cell Dev Biol. 1990 Jul;26(7):722-30 [2384450.001]
  • [Cites] Cell. 1991 Jan 25;64(2):231 [1846319.001]
  • [Cites] Acta Anat (Basel). 1992;143(2):139-50 [1598820.001]
  • [Cites] J Cell Sci. 1992 Jun;102 ( Pt 2):361-72 [1400638.001]
  • [Cites] Cancer. 1994 Aug 1;74(3 Suppl):1030-44 [8039137.001]
  • [Cites] Carcinogenesis. 1995 Jul;16(7):1499-503 [7614683.001]
  • [Cites] J Urol. 1995 Oct;154(4):1295-9 [7544835.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5408-14 [7585610.001]
  • [Cites] J Histochem Cytochem. 1998 Mar;46(3):379-88 [9487120.001]
  • [Cites] Cancer Res. 1998 Jun 15;58(12):2520-3 [9635571.001]
  • [Cites] Clin Cancer Res. 1998 Jul;4(7):1625-30 [9676836.001]
  • [Cites] J Immunol. 1998 Aug 15;161(4):1772-7 [9712043.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Clin Cancer Res. 1996 Aug;2(8):1255-61 [9816295.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5329-32 [9850059.001]
  • [Cites] Genes Cells. 1998 Oct;3(10):659-70 [9893023.001]
  • [Cites] Mol Cancer. 2007;6:69 [17967179.001]
  • [Cites] Bioessays. 1999 Dec;21(12):1021-30 [10580987.001]
  • [Cites] Nature. 2000 Feb 17;403(6771):781-5 [10693808.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):2078-93 [15774796.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2005;8(2):119-26 [15809669.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5153-62 [15958559.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):29-40 [16289860.001]
  • [Cites] Oncogene. 2006 May 4;25(19):2773-84 [16407846.001]
  • [Cites] Cancer Lett. 2006 Jun 8;237(1):22-32 [16023783.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] Rev Endocr Metab Disord. 2006 Jun;7(1-2):41-9 [16944325.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):320-4 [9927040.001]
  • [Cites] Growth Factors. 1998;16(2):101-10 [9932228.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1366-71 [10096572.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):598-606 [17258791.001]
  • (PMID = 18724388.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA108646; United States / NIGMS NIH HHS / GM / F31 GM079879; United States / PHS HHS / / FGM079879A; United States / NCI NIH HHS / CA / U54 CA126505; United States / NCI NIH HHS / CA / CA126505; United States / NCI NIH HHS / CA / R01 CA108646-04; United States / NCI NIH HHS / CA / T32 CA009592; United States / NCI NIH HHS / CA / R01 CA108646; None / None / / R01 CA108646-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ligands; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; 0 / WNT3A protein, human; 0 / Wnt Proteins; 0 / Wnt3 Protein; 0 / Wnt3A Protein; 0 / Wnt3a protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  • [Other-IDs] NLM/ NIHMS142310; NLM/ PMC3222150
  •  go-up   go-down


22. Mittal R, Perakath B, Chase S, Jesudason MR, Nayak S: Transanal excision of anorectal lesions--a single centre experience. Trop Gastroenterol; 2010 Jan-Mar;31(1):65-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were divided into three groups. (1) Resection for benign disease (2) Curative and (3) Palliative resection for malignant disease.
  • RESULTS: Forty six patients underwent transanal excision, 21 for benign and 25 for malignant disease, 20 with curative and 5 with palliative intent.
  • Tubulovillous adenomas and hyperplastic polyps were the commonest benign lesions.
  • CONCLUSION: Transanal excision, when technically feasible, remains the treatment of choice for benign disease of the rectum.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Palliative Care. Postoperative Complications. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20860237.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


23. Tang HW, Luo MN, Li T, Pan L: Quantitative DNA imaging in breast tumor cells by a Hadamard transform fluorescence imaging microscope. Anal Sci; 2006 May;22(5):701-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative DNA imaging in breast tumor cells by a Hadamard transform fluorescence imaging microscope.
  • In this study, the high potential value of the microscope in biomedical analysis has been demonstrated by using it to evaluate the malignancy degree of thirty cases of human breast tumors based on the measurements of cellular DNA contents, with conclusions highly accordant with pathological diagnosis.
  • The microscope was also successfully applied to cellular morphological analysis, and it was demonstrated that a significant linear relationship exists between tumor nuclear DNA contents and the nuclear area, and malignant and benign tumors are significantly different in both DNA contents and nuclear area.
  • [MeSH-major] Breast Neoplasms / pathology. DNA, Neoplasm / analysis
  • [MeSH-minor] Female. Humans. Image Cytometry. Microscopy, Fluorescence. Ploidies. Sensitivity and Specificity. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770048.001).
  • [ISSN] 0910-6340
  • [Journal-full-title] Analytical sciences : the international journal of the Japan Society for Analytical Chemistry
  • [ISO-abbreviation] Anal Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


24. Thysell E, Surowiec I, Hörnberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikström P: Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One; 2010;5(12):e14175
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODOLOGY/PRINCIPAL FINDINGS: Metabolomics was applied for the study of PCa bone metastases (n = 20) in comparison with corresponding normal bone (n = 14), and furthermore of malignant (n = 13) and benign (n = 17) prostate tissue and corresponding plasma samples obtained from patients with (n = 15) and without (n = 13) diagnosed metastases and from men with benign prostate disease (n = 30).
  • Furthermore, we identified metabolites in primary tumor tissue and in plasma which were significantly associated with metastatic disease.
  • Immunohistochemical staining of PCa bone metastases showed intense staining of the low density lipoprotein receptor and variable levels of the scavenger receptor class B type 1 and 3-hydroxy-3-methylglutaryl-coenzyme reductase in tumor epithelial cells, indicating possibilities for influx and de novo synthesis of cholesterol.
  • [MeSH-minor] Biopsy. Bone and Bones / pathology. Computational Biology / methods. Gas Chromatography-Mass Spectrometry / methods. Humans. Immunohistochemistry / methods. Male. Neoplasm Metastasis. Prostatic Neoplasms / pathology. Sarcosine / metabolism. Tissue Distribution

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Prev. 2001 Dec;10(6):507-13 [11916349.001]
  • [Cites] PLoS One. 2009;4(9):e7075 [19763266.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12027-32 [14512514.001]
  • [Cites] Magn Reson Med. 2003 Nov;50(5):944-54 [14587005.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jan;36(1):39-77 [14592533.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Jul;24(7):1150-60 [15130918.001]
  • [Cites] Prog Clin Biol Res. 1981;75A:279-324 [6175978.001]
  • [Cites] Science. 1986 Apr 4;232(4746):34-47 [3513311.001]
  • [Cites] Prostate. 1992;20(2):151-8 [1549552.001]
  • [Cites] Magn Reson Med. 1992 May;25(1):140-7 [1375702.001]
  • [Cites] Magn Reson Med. 1993 Feb;29(2):149-57 [8429778.001]
  • [Cites] J Urol. 1993 Dec;150(6):2019-24 [7693985.001]
  • [Cites] JAMA. 1998 May 20;279(19):1542-7 [9605898.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3A):1429-34 [9673351.001]
  • [Cites] J Urol. 1999 Jan;161(1):152-5 [10037388.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):959-68 [15776112.001]
  • [Cites] Anal Chem. 2005 Sep 1;77(17):5635-42 [16131076.001]
  • [Cites] Anal Chem. 2005 Dec 15;77(24):8086-94 [16351159.001]
  • [Cites] J Proteome Res. 2006 Jun;5(6):1407-14 [16739992.001]
  • [Cites] Urology. 2006 Jun;67(6):1205-11 [16765180.001]
  • [Cites] Curr Treat Options Oncol. 2006 Sep;7(5):355-62 [16904052.001]
  • [Cites] Mol Cancer Ther. 2006 Sep;5(9):2310-6 [16985065.001]
  • [Cites] Mol Endocrinol. 2006 Oct;20(10):2265-77 [16455816.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10795-804 [17108116.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 20;98(24):1819-25 [17179483.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):41-51 [17173048.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):256-69 [17384581.001]
  • [Cites] J Urol. 2007 Dec;178(6):2252-9 [17936845.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2213-7 [17971518.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2218-25 [17971519.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2226-32 [18006910.001]
  • [Cites] J Pharmacol Sci. 2008 Apr;106(4):536-41 [18431036.001]
  • [Cites] Trends Endocrinol Metab. 2008 May-Jun;19(4):113-21 [18356074.001]
  • [Cites] J Urol. 2008 Jun;179(6):2422-6 [18433783.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4447-54 [18519708.001]
  • [Cites] Mol Cancer. 2008;7:72 [18799019.001]
  • [Cites] Cancer Biomark. 2008;4(4-5):263-76 [18957715.001]
  • [Cites] Mol Cell Endocrinol. 2008 Nov 25;295(1-2):115-20 [18782595.001]
  • [Cites] Cancer Causes Control. 2008 Dec;19(10):1259-66 [18704722.001]
  • [Cites] J Proteome Res. 2009 Jan;8(1):352-61 [19063642.001]
  • [Cites] Cancer Treat Rev. 2009 Feb;35(1):1-8 [18778896.001]
  • [Cites] Nature. 2009 Feb 12;457(7231):910-4 [19212411.001]
  • [Cites] Am J Pathol. 2009 Mar;174(3):1017-26 [19179610.001]
  • [Cites] Cancer. 2009 Jul 1;115(13 Suppl):3058-67 [19544547.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2807-13 [19887582.001]
  • [Cites] Clin Exp Metastasis. 2009;26(7):781-7 [19526315.001]
  • [Cites] Endocr Relat Cancer. 2010 Dec;17(4):885-95 [20688881.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2227-31 [11956073.001]
  • (PMID = 21151972.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 97C5T2UQ7J / Cholesterol; Z711V88R5F / Sarcosine
  • [Other-IDs] NLM/ PMC2997052
  •  go-up   go-down


25. Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, Tindall DJ, Cantor CR, Young CY: Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest; 2009 Jun;27(5):549-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of genes for diagnosis and risk stratification of prostate cancer.
  • To identify the relevant CpG sites as molecular markers, for the diagnosis and to distinguish the indolent and aggressive prostate tumors, we have determined the methylation status of 8 genes, including FLNC, EFS, ECRG4, RARB2, PITX2, GSTP1, PDLIM4, and KCNMA1 in 32 nonrecurrent, 32 recurrent primary prostate tumors, and 32 benign prostate tissues using EpiTYPER technology.
  • Specific CpG site hypermethylation of RARB2 and GSTP1 CpG sites were useful for diagnosis of prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1128-36 [16489065.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10911-8 [17108128.001]
  • [Cites] JAMA. 2006 May 17;295(19):2234-8 [16705097.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3973-8 [16921049.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4236-44 [16896004.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2317-21 [17119066.001]
  • [Cites] Genes Dev. 2006 Dec 1;20(23):3215-31 [17158741.001]
  • [Cites] Eur Urol. 2007 Mar;51(3):665-74; discussion 674 [16956712.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5941-5 [11085508.001]
  • [Cites] J Urol. 2001 Jan;165(1):119-25 [11125379.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1815-26 [11696442.001]
  • [Cites] Urology. 2001 Jun;57(6):1033-7 [11377299.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3740-5 [11891299.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):203-9 [12086878.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3376-85 [12177097.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • [Cites] Urology. 2003 Feb;61(2):365-9 [12597949.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):253-66 [12671664.001]
  • [Cites] World J Gastroenterol. 2003 Jun;9(6):1174-8 [12800218.001]
  • [Cites] Bioinformatics. 2003 Jun 12;19(9):1100-9 [12801870.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3877-82 [12873976.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6 [14711987.001]
  • [Cites] J Pathol. 2004 Feb;202(2):233-40 [14743506.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1975-86 [15026333.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1633-8 [15073850.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 May 1;196(3):422-30 [15094313.001]
  • [Cites] Urologe A. 2004 May;43(5):573-9 [15029477.001]
  • [Cites] N Engl J Med. 2004 May 27;350(22):2239-46 [15163773.001]
  • [Cites] Nature. 2004 May 27;429(6990):457-63 [15164071.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3935-6 [15217922.001]
  • [Cites] N Engl J Med. 2004 Jul 8;351(2):125-35 [15247353.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2790-9 [15254046.001]
  • [Cites] Eur Urol. 2004 Nov;46(5):660-9; discussion 669 [15474280.001]
  • [Cites] J Mol Biol. 1987 Jul 20;196(2):261-82 [3656447.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Feb 1;34(3):549-53 [8621277.001]
  • [Cites] Anal Biochem. 1998 Sep 10;262(2):185-92 [9750131.001]
  • [Cites] Clin Chim Acta. 2004 Dec;350(1-2):181-8 [15530476.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8472-8 [15623627.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):103-15 [15657340.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4037-43 [15930338.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6582-8 [16166436.001]
  • [Cites] J Urol. 2005 Dec;174(6):2191-6 [16280762.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):393-406 [16286247.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8321-5 [16322291.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 15;98(4):255-61 [16478744.001]
  • [Cites] Nat Rev Drug Discov. 2006 Jan;5(1):37-50 [16485345.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Cancer J. 2007 Jan-Feb;13(1):17-22 [17464242.001]
  • [Cites] J Urol. 2007 Aug;178(2):459-63; discussion 463 [17561132.001]
  • [Cites] Eur J Cancer. 2007 Jul;43(11):1679-86 [17601725.001]
  • [Cites] J Urol. 2008 Apr;179(4):1354-60; discussion 1360-1 [18289596.001]
  • [Cites] J Urol. 2008 Jun;179(6):2207-10; discussion 2210-1 [18423693.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):659-64 [18692327.001]
  • [Cites] J Urol. 2006 Dec;176(6 Pt 2):S11-5 [17084157.001]
  • [Cites] J Natl Cancer Inst. 2006 May 17;98(10):715-7 [16705126.001]
  • (PMID = 19229700.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA091956-080012; United States / NCI NIH HHS / CA / P50 CA091956; United States / NCI NIH HHS / CA / CA091956; United States / NCI NIH HHS / CA / P50 CA091956-080012
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ NIHMS99244; NLM/ PMC2693083
  •  go-up   go-down


26. Cho SD, Herzig DO, Douthit MA, Deveney KE: Treatment strategies and outcomes for rectal villous adenoma from a single-center experience. Arch Surg; 2008 Sep;143(9):866-70; discussion 871-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: Retrospective review of patient and tumor characteristics, procedure, recurrence, and complications.
  • Mean tumor size was 3.0 cm (range, 0.5-11 cm) and the mean distance of the tumor from the anal verge was 4.9 cm (range, 0-10 cm).
  • Tumor size did not correlate with malignancy.
  • There were 4 (12.5%) benign recurrences, all after transanal excisions.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Endosonography. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794424.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Mohler JL: A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract Res Clin Endocrinol Metab; 2008 Apr;22(2):357-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Earlier studies of androgen-receptor (AR) expression using frozen prostate tissue, and later studies using archived specimens, produced the consensus that ligand-stabilized AR is nuclear, AR expression is similar in benign epithelia and stroma, AR expression is greater in secretory epithelia than basal cells, and AR expression is more variable in prostate cancer (CaP) than in benign prostatic hyperplasia (BPH).

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytometry. 1999 Jan 1;35(1):2-10 [10554175.001]
  • [Cites] Endocr Relat Cancer. 1999 Dec;6(4):487-502 [10730903.001]
  • [Cites] Cancer. 2000 May 15;88(10):2398-424 [10820364.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):423-7 [11212224.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2892-8 [11306464.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3550-5 [11325816.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4315-9 [11389051.001]
  • [Cites] J Natl Cancer Inst. 2001 Nov 21;93(22):1687-97 [11717329.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):219-26 [11786415.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):34-45 [11900250.001]
  • [Cites] Endocr Relat Cancer. 2002 Mar;9(1):61-73 [11914183.001]
  • [Cites] J Urol. 2002 Jul;168(1):9-12 [12050481.001]
  • [Cites] Curr Urol Rep. 2002 Feb;3(1):67-74 [12084222.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):3001-15 [12089231.001]
  • [Cites] Eur J Surg Oncol. 2003 Feb;29(1):20-4 [12559071.001]
  • [Cites] J Urol. 2003 Sep;170(3):990-3 [12913756.001]
  • [Cites] J Urol. 2003 Nov;170(5):1817-21 [14532783.001]
  • [Cites] Nat Med. 2004 Jan;10(1):33-9 [14702632.001]
  • [Cites] J Clin Pathol. 2004 Feb;57(2):146-50 [14747438.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):440-8 [14760063.001]
  • [Cites] Comput Methods Programs Biomed. 2004 Jul;75(1):75-9 [15158050.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):928-34 [15223964.001]
  • [Cites] Anal Quant Cytol Histol. 1994 Dec;16(6):400-14 [7536003.001]
  • [Cites] N Engl J Med. 1995 May 25;332(21):1393-8 [7723794.001]
  • [Cites] Nat Genet. 1995 Apr;9(4):401-6 [7795646.001]
  • [Cites] Lab Invest. 1995 Aug;73(2):302-5 [7637331.001]
  • [Cites] Prostate. 1996 Apr;28(4):251-65 [8602401.001]
  • [Cites] J Urol. 1998 Mar;159(3):641-9 [9474117.001]
  • [Cites] J Urol. 1998 Feb;159(2):548-54 [9649289.001]
  • [Cites] Mol Carcinog. 1993;7(3):165-79 [8489712.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1991 Nov-Dec;1(1):21-7 [1845164.001]
  • [Cites] J Urol. 1993 Aug;150(2 Pt 1):379-85 [8326560.001]
  • [Cites] Cancer Res. 1994 Aug 1;54(15):4096-102 [7518349.001]
  • [Cites] Ann Surg Oncol. 1994 Nov;1(6):495-503 [7531602.001]
  • [Cites] Clin Cancer Res. 1996 May;2(5):889-95 [9816246.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):569-76 [10100708.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2511-5 [10363963.001]
  • [Cites] Cancer Metastasis Rev. 1998-1999;17(4):411-9 [10453285.001]
  • [Cites] Prostate. 2005 Apr 1;63(1):19-28 [15378523.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):309-19 [17045208.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10594-602 [17079484.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 15;104(20):8438-43 [17494760.001]
  • [Cites] Prostate. 2008 Jun 1;68(8):830-8 [18324648.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):934-40 [8608487.001]
  • [Cites] J Natl Cancer Inst. 1980 Aug;65(2):311-6 [6931251.001]
  • [Cites] J Urol. 1984 Apr;131(4):694-700 [6708184.001]
  • [Cites] Cancer. 1985 Jan 15;55(2):382-8 [2578085.001]
  • [Cites] Cancer. 1986 Jun 15;57(12):2351-6 [2421868.001]
  • [Cites] Science. 1988 Apr 15;240(4850):324-6 [3353726.001]
  • [Cites] Science. 1988 Apr 15;240(4850):327-30 [3353727.001]
  • [Cites] Arch Pathol Lab Med. 1988 Aug;112(8):787-90 [3395214.001]
  • [Cites] Mol Endocrinol. 1988 Dec;2(12):1265-75 [3216866.001]
  • [Cites] J Steroid Biochem. 1989;34(1-6):311-3 [2626023.001]
  • [Cites] J Pathol. 1990 Apr;160(4):329-32 [2193135.001]
  • [Cites] Ann N Y Acad Sci. 1990;595:53-66 [1695829.001]
  • [Cites] Prostate. 1990;17(4):293-300 [1701248.001]
  • [Cites] Int J Cancer. 1991 May 10;48(2):189-93 [1708363.001]
  • [Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]
  • [Cites] Cancer. 1991 Jun 15;67(12):3057-64 [1710537.001]
  • [Cites] J Urol. 1992 Mar;147(3 Pt 2):798-803 [1371552.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2574-80 [7680949.001]
  • [Cites] J Urol. 1993 May;149(5):1015-9 [7683339.001]
  • (PMID = 18471792.001).
  • [ISSN] 1521-690X
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA077739-100006; United States / NCI NIH HHS / CA / P01 CA077739; United States / NCI NIH HHS / CA / CA 77739; United States / NCI NIH HHS / CA / P01 CA077739-100006
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Receptors, Androgen
  • [Number-of-references] 76
  • [Other-IDs] NLM/ NIHMS52370; NLM/ PMC2799036
  •  go-up   go-down


28. Balducci C, Lilli C, Stabellini G, Marinucci L, Giustozzi G, Becchetti A, Cagini L, Locci P: Human desmoid fibroblasts: matrix metalloproteinases, their inhibitors and modulation by Toremifene. BMC Cancer; 2005 Mar 1;5:22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Desmoid tumour is a benign, non metastasising neoplasm characterised by an elevated deposition of organic macromolecules in the extracellular matrix (ECM).
  • The MMPs and their natural inhibitors (TIMPs) have been implicated in tumour growth, invasion and metastasis.
  • In this study we provide evidence that the in vitro cultured cell line from desmoid tumour accumulates more collagen fibres in the ECM than healthy fibroblasts.
  • [MeSH-minor] Antineoplastic Agents, Hormonal / pharmacology. Cell Line, Tumor. Collagenases / metabolism. Humans. Matrix Metalloproteinase Inhibitors. Procollagen / analysis. Tissue Inhibitor of Metalloproteinases / metabolism. Tumor Cells, Cultured. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Interferon Cytokine Res. 2001 Nov;21(11):961-70 [11747628.001]
  • [Cites] Mol Cell Biochem. 1999 Apr;194(1-2):99-108 [10391129.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):824-32 [11948458.001]
  • [Cites] J Periodontol. 2002 Nov;73(11):1313-22 [12479636.001]
  • [Cites] Biol Reprod. 2003 Apr;68(4):1276-81 [12606436.001]
  • [Cites] Biochem J. 2003 Sep 15;374(Pt 3):739-45 [12755684.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):40364-72 [12904305.001]
  • [Cites] Cancer Lett. 2003 Oct 8;200(1):49-55 [14550952.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1979 Jul 1;96(1):220-4 [495986.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Eur J Cancer. 1992;28A(6-7):1014-8 [1385717.001]
  • [Cites] Crit Rev Oral Biol Med. 1993;4(2):197-250 [8435466.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Aug 11;261(3):904-10 [10441523.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Anal Biochem. 1998 Jan 15;255(2):211-6 [9451506.001]
  • [Cites] J Biol Chem. 1995 Mar 17;270(11):5872-6 [7890717.001]
  • [Cites] Aust N Z J Surg. 1996 Jul;66(7):457-63 [8678875.001]
  • [Cites] Am J Hum Genet. 1996 Dec;59(6):1193-201 [8940264.001]
  • [Cites] Eur J Cell Biol. 1997 Oct;74(2):111-22 [9352216.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1359-66 [9529029.001]
  • [Cites] Cytokine. 1998 May;10(5):353-60 [9619373.001]
  • [Cites] Pathol Int. 1998 Aug;48(8):603-10 [9736407.001]
  • [Cites] Curr Opin Cell Biol. 1998 Oct;10(5):602-8 [9818170.001]
  • [Cites] Curr Opin Cell Biol. 1998 Oct;10(5):667-71 [9818179.001]
  • [Cites] Gut. 1998 Dec;43(6):791-7 [9824606.001]
  • [Cites] Ann Med. 1999 Feb;31(1):34-45 [10219712.001]
  • [Cites] Int J Dev Biol. 1999 Mar;43(2):157-65 [10235392.001]
  • [Cites] Am J Physiol. 1999 May;276(5 Pt 1):L814-24 [10330038.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):866-72; discussion 872-3 [10363901.001]
  • [Cites] Cell. 2000 Oct 13;103(2):295-309 [11057902.001]
  • [Cites] Curr Med Chem. 2001 Mar;8(4):425-74 [11172697.001]
  • [Cites] Int J Cancer. 2001 Aug 15;93(4):507-15 [11477554.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2396-404 [11489818.001]
  • [Cites] J Natl Cancer Inst. 2002 Jan 2;94(1):17-25 [11773278.001]
  • (PMID = 15740610.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Matrix Metalloproteinase Inhibitors; 0 / Procollagen; 0 / Tissue Inhibitor of Metalloproteinases; 7NFE54O27T / Toremifene; 9007-34-5 / Collagen; EC 3.4.24.- / Collagenases; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ PMC555538
  •  go-up   go-down


29. Kim HJ, Lee KY, Kim YW: Case report: Imaging features of perianal leiomyoma. Br J Radiol; 2009 Aug;82(980):e168-70
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A leiomyoma is a benign mesenchymal neoplasm that usually develops where smooth muscle is present.
  • The external anal sphincter was stretched over the surface of the leiomyoma and the internal anal sphincter was intact on surgery.
  • [MeSH-major] Anal Canal. Anus Neoplasms / diagnosis. Leiomyoma / diagnosis
  • [MeSH-minor] Adult. Contrast Media. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Br J Radiol. 2010 Jan;83(985):88. Lee, G H [corrected to Lee, K Y]
  • (PMID = 19592401.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


30. Lee MW, Chung WK, Choi JH, Moon KC, Koh JK: A case of botryoid-type embryonal rhabdomyosarcoma. Clin Exp Dermatol; 2009 Dec;34(8):e737-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe an infant with a congenital polypoid anal mass, diagnosed as botryoid-type embryonal rhabdomyosarcoma.
  • Tumour cells were strongly immunoreactive for desmin and 10% of cells displayed immunoreactivity for myoglobin.
  • We present this case with a view to highlighting the benign clinical and histological appearance of botryoid-type embryonal rhabdomyosarcoma.
  • [MeSH-major] Anus Neoplasms / pathology. Rhabdomyosarcoma, Embryonal / pathology
  • [MeSH-minor] Desmin / analysis. Early Detection of Cancer. Humans. Infant. Male. Neoplasm Proteins / analysis. Prognosis

  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19663848.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Desmin; 0 / Neoplasm Proteins
  •  go-up   go-down


31. Taylor DD, Gercel-Taylor C, Parker LP: Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol; 2009 Oct;115(1):112-20
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.
  • OBJECTIVE: Most ovarian cancers are diagnosed at advanced stage (67%) and prospects for significant improvement in survival reside in early diagnosis.
  • Our objective was to validate our array assay for the identification of ovarian cancer based on quantitation of tumor-reactive IgG.
  • Specific protein targets were isolated by immunoaffinity from exosomes derived from ovarian tumor cell lines.
  • Sera were obtained from age-matched female volunteers, women with benign ovarian disease and with ovarian cancer.
  • RESULTS: Sera from ovarian cancer patients exhibited significantly greater immunoreactivities than either normal controls or women with benign disease (both considered negative to all antigens tested).
  • Reactivities with nucleophosmin, cathepsin D, p53, and SSX common antigen for patients with all stages of ovarian cancer were significantly higher than for controls and women with benign ovarian disease.
  • CONCLUSIONS: The quantitation of circulating tumor-reactive IgG can be used to identify the presence of ovarian cancer.
  • The analyses of IgG recognition of specific exosomal antigens allows for the differentiation of women with benign ovarian masses from ovarian cancer, as well as distinguishing early and late stage ovarian cancers.
  • Thus, the quantitative assessment of IgG reactive with specific tumor-derived exosomal proteins can be used as diagnostic markers for ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1993 Oct 21;55(4):678-84 [8406999.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):26-35 [8380118.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:189-99 [8747396.001]
  • [Cites] J Soc Gynecol Investig. 1996 Jul-Aug;3(4):216-22 [8796833.001]
  • [Cites] Gynecol Oncol. 1997 Apr;65(1):13-22 [9103385.001]
  • [Cites] Cancer Lett. 1997 Jun 3;116(1):93-101 [9177463.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1163-7 [9547328.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1519-24 [9769398.001]
  • [Cites] J Proteome Res. 2005 Jul-Aug;4(4):1123-33 [16083262.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Sep;5(5):735-43 [16149876.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1288-90 [16177255.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81 [16343244.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1181-90 [16424057.001]
  • [Cites] Biochim Biophys Acta. 2006 Apr;1762(4):398-403 [16483750.001]
  • [Cites] PLoS One. 2007;2(12):e1281 [18060075.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):764-71 [18245537.001]
  • [Cites] Adv Exp Med Biol. 2008;622:15-21 [18546615.001]
  • [Cites] PLoS Med. 2008 Aug 19;5(8):e170 [18715113.001]
  • [Cites] Am J Obstet Gynecol. 2008 Sep;199(3):215-23 [18468571.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2009 Feb;142(2):99-105 [18995946.001]
  • [Cites] Methods Mol Biol. 2009;520:21-38 [19381945.001]
  • [Cites] Clin Biochem. 2000 Feb;33(1):53-62 [10693987.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;46 Suppl:S3-7 [10950139.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1338-43 [11044359.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4060-5 [11274429.001]
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):71-6 [11277653.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):138-43 [11330940.001]
  • [Cites] Cancer Detect Prev. 2001;25(2):117-22 [11341346.001]
  • [Cites] Int J Oncol. 2001 Aug;19(2):387-94 [11445857.001]
  • [Cites] J Reprod Med. 2001 Jul;46(7):621-9; discussion 629-30 [11499181.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7908-12 [11691811.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14571-6 [11724951.001]
  • [Cites] Int J Cancer. 2001 Dec 15;94(6):859-63 [11745489.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):168s-174s [12743131.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):512-8 [15234232.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):720-6 [15252841.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1979 Sep 15;98(1):53-9 [396817.001]
  • [Cites] Am J Reprod Immunol. 1984 Dec;6(4):179-84 [6528883.001]
  • [Cites] Cancer Res. 1989 Mar 15;49(6):1361-5 [2924293.001]
  • [Cites] Am J Pathol. 1992 Apr;140(4):859-70 [1314027.001]
  • [Cites] Lancet. 1995 Jan 14;345(8942):126 [7815863.001]
  • (PMID = 19647308.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA098166-02; United States / NCI NIH HHS / CA / R21 CA098166-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Epitopes; 0 / Immunoglobulin G
  • [Other-IDs] NLM/ NIHMS129188; NLM/ PMC2760307
  •  go-up   go-down


32. Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL: Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol; 2008 Jan 1;26(1):96-105
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We tested the hypothesis that individual CSF proteins distinguish CNS lymphoma from benign focal brain lesions.
  • ATIII RNA transcripts were identified within CNS lymphomas, and ATIII protein was localized selectively to tumor neovasculature.
  • We propose that the discovery of CSF protein biomarkers will facilitate early and noninvasive diagnosis in patients with lesions not amenable to brain biopsy, as well as provide improved surrogates of prognosis and treatment response in CNS lymphoma and brain metastasis.
  • [MeSH-major] Biomarkers, Tumor / cerebrospinal fluid. Brain Neoplasms / cerebrospinal fluid. Lymphoma / cerebrospinal fluid. Neoplasm Proteins / cerebrospinal fluid
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antithrombin III / genetics. Antithrombin III / metabolism. Case-Control Studies. Chromatography, Liquid. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoblotting. Immunoenzyme Techniques. Leukemia, Myeloid / cerebrospinal fluid. Leukemia, Myeloid / pathology. Lymphoma, B-Cell / cerebrospinal fluid. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / cerebrospinal fluid. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / cerebrospinal fluid. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / cerebrospinal fluid. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Proteomics. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Feb;17(2):554-60 [10080599.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3575-82 [15284095.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):705-17, vii [16083831.001]
  • [Cites] Mol Cell Proteomics. 2005 Sep;4(9):1341-9 [15970584.001]
  • [Cites] Dis Markers. 2006;22(1-2):3-26 [16410649.001]
  • [Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]
  • [Cites] J Biol Chem. 2006 Dec 8;281(49):37302-10 [17040907.001]
  • [Cites] Expert Rev Mol Med. 2006;8(31):1-19 [17156576.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Anal Chem. 2003 Sep 15;75(18):4818-26 [14674459.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2053-63 [12466122.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Curr Opin Neurol. 2000 Dec;13(6):641-8 [11148663.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]
  • [Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]
  • [Cites] Br J Haematol. 2004 Jul;126(2):202-8 [15238140.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2922-7 [15131026.001]
  • [Cites] Bioinformatics. 2004 Mar 22;20(5):777-85 [14751995.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1):72-5 [17236490.001]
  • [CommentIn] J Clin Oncol. 2009 May 1;27(13):2302-3; author reply 2303-4 [19332721.001]
  • (PMID = 18056677.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA100291
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 9000-94-6 / Antithrombin III
  • [Other-IDs] NLM/ NIHMS612770; NLM/ PMC4134101
  •  go-up   go-down


33. Platell C: Transanal endoscopic microsurgery. ANZ J Surg; 2009 Apr;79(4):275-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median neoplasia area was 12 cm(2) (IQR, 6-25 cm(2)) and the median height above the anal verge was 9 cm (IQR, 3-17 cm).
  • During a median follow up of 4.2 years (IQR, 2.6-6.2 years), the 5-year cumulative incidence for local recurrence for benign pathology was 3.1% (95% confidence interval (CI): 1.2-6.7%, n = 180) and for cancers managed primarily by TEM excision it was 8.5% (95%CI: 1.4-23.9%, n = 36).
  • TEM is an excellent treatment modality for benign rectal neoplasias of any size, and in any location.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Endoscopy, Digestive System. Female. Humans. Male. Microsurgery. Middle Aged. Morbidity. Neoplasm Recurrence, Local / epidemiology. Prospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432714.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


34. Nese N, Kandiloglu AR, Simsek G, Lekili M, Ozdamar A, Catalkaya A, Coskun T: Comparison of the desmoplastic reaction and invading ability in invasive ductal carcinoma of the breast and prostatic adenocarcinoma based on the expression of heat shock protein 47 and fascin. Anal Quant Cytol Histol; 2010 Apr;32(2):90-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: HSP47 and fascin were localized to cytoplasm, and HSP47 and fascin IR were higher in IDC and PCa than benign groups (p < 0.05).
  • Fascin expression correlated with estrogen receptor and progesterone receptor negativity, tumor size and stage in IDC and surgical margin status in PCa.
  • Although there is no relationship with recurrence or metastatic status, fascin overexpression correlated with tumor size, which may prompt its use as a prognostic factor in IDC.

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701077.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / FSCN1 protein, human; 0 / HSP47 Heat-Shock Proteins; 0 / Microfilament Proteins
  •  go-up   go-down


35. Nakao A, Takeda S, Nomoto S, Kanazumi N, Kasuya H, Sugimoto H, Fujii T, Yamada S: Pancreatic head resection with segmental duodenectomy for pancreatic neoplasms. J Hepatobiliary Pancreat Sci; 2010 Nov;17(6):788-91
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/PURPOSE: We have experienced 67 cases of pancreatic head resection with segmental duodenectomy (PHRSD) for benign or low-grade malignant tumor of the pancreatic head region.
  • In addition, by conserving the anterior inferior pancreatoduodenal artery, the third portion and anal side or the second portion of the duodenum are preserved with good arterial circulation.
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / surgery. Choledochostomy / methods. Follow-Up Studies. Humans. Neoplasm Staging. Quality of Life. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19882374.001).
  • [ISSN] 1868-6982
  • [Journal-full-title] Journal of hepato-biliary-pancreatic sciences
  • [ISO-abbreviation] J Hepatobiliary Pancreat Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


36. Rosenblatt R, Valdman A, Cheng L, Lopez-Beltran A, Montironi R, Ekman P, Egevad L: Endothelin-1 expression in prostate cancer and high grade prostatic intraepithelial neoplasia. Anal Quant Cytol Histol; 2009 Jun;31(3):137-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endothelin-1 expression in prostate cancer and high grade prostatic intraepithelial neoplasia.
  • We separately arrayed benign prostatic tissue, atrophy, high grade prostatic intraepithelial neoplasia (HGPIN) and prostate cancer from 40 men.
  • RESULTS: ET-1 expression was stronger in both HGPIN and cancer than in benign tissue (p < 0.001).

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19634784.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Endothelin-1
  •  go-up   go-down


37. Jasiński A, Szyca R, Tomaszewski S, Leksowski K: [Long-term results of rectal tumors treatment by transanal endoscopic microsurgery (TEM)]. Pol Merkur Lekarski; 2007 May;22(131):379-80
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transanal endoscopic microsurgery (TEM) is a minimally invasive technique for excision of selected benign and malignant rectal neoplasmas.
  • The aim of this study was to assess the long-term results after benign and malignant rectal lesions excision using TEM.
  • CONCLUSION: TEM is a safe, effective treatment for selected cases of benign lesions and some cases of early stage rectal cancer.
  • [MeSH-major] Adenoma / surgery. Anal Canal / surgery. Endoscopy, Gastrointestinal. Liver Neoplasms / secondary. Microsurgery. Rectal Neoplasms / surgery. Rectum / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anastomosis, Surgical. Digestive System Surgical Procedures. Female. Follow-Up Studies. Humans. Longitudinal Studies. Male. Middle Aged. Neoplasm Recurrence, Local. Recovery of Function. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679373.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


38. Cumberland L, Dana A, Resh B, Fitzpatrick J, Goldenberg G: Verruciform xanthoma in the setting of cutaneous trauma and chronic inflammation: report of a patient and a brief review of the literature. J Cutan Pathol; 2010 Aug;37(8):895-900
MedlinePlus Health Information. consumer health - Anal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • VX is a rare benign mucocutaneous neoplasm that typically presents as a solitary lesion with a predilection for the oral cavity, although extra-oral lesions have been reported involving the vulva, scrotum, penis, anal region and extremities.
  • [MeSH-major] Anus Diseases / pathology. Xanthomatosis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cutan Pathol. 2012 Mar;39(3):391-4 [21362016.001]
  • (PMID = 19958440.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


39. Nonose R, Priolli DG, Cardinalli IA, Máximo FR, Galvão PS, Martinez CA: Epithelioid hemangioma of the colon: a case report. Sao Paulo Med J; 2008 Sep;126(5):294-6
MedlinePlus Health Information. consumer health - Birthmarks.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Epithelioid hemangioma or angiolymphoid hyperplasia with eosinophilia is an uncommon benign vascular neoplasm that is usually located on the face or neck.
  • Neoplasia of the colon was clinically suspected and she underwent colonoscopy.
  • This demonstrated the presence of a vegetating sessile lesion of approximately 5 cm in diameter, at a distance of 36 cm from the anal margin.
  • A biopsy collected during the examination suggested a diagnosis of neoplasia of vascular origin.
  • After surgical resection, histopathological examination of the resected specimen confirmed the diagnosis of epithelioid hemangioma of the colon, which was backed up by the immunohistochemical panel (factor VIII, Ki-67, CD-34).
  • Despite the rarity of neoplasia of vascular origin, this possibility should be considered in the differential diagnosis for colorectal tumors.
  • [MeSH-minor] Abdominal Pain. Adult. Colonoscopy. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19099166.001).
  • [ISSN] 1806-9460
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


40. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS: Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn; 2005 Aug;7(3):413-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both benign and malignant tumors represent heterogenous tissue containing tumor cells and non-neoplastic mesenchymal and inflammatory cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Biol. 2001 Mar;8(3):243-52 [11306349.001]
  • [Cites] Clin Chem. 2002 Mar;48(3):428-35 [11861435.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Mar;11(3):227-34 [11895870.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5261-6 [11959976.001]
  • [Cites] Hum Mutat. 2002 May;19(5):479-85 [11968080.001]
  • [Cites] J Mol Diagn. 2002 Nov;4(4):185-90 [12411585.001]
  • [Cites] Clin Chem. 2002 Dec;48(12):2164-70 [12446472.001]
  • [Cites] Electrophoresis. 2002 Dec;23(24):4072-9 [12481262.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):146-50 [12866414.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):152-6 [12866415.001]
  • [Cites] J Mol Diagn. 2003 Nov;5(4):243-9 [14573784.001]
  • [Cites] Mol Biotechnol. 2004 Feb;26(2):147-64 [14764940.001]
  • [Cites] Nucleic Acids Res. 2004;32(5):e53 [15037663.001]
  • [Cites] Hum Mutat. 2004 May;23(5):406-12 [15108270.001]
  • [Cites] Hum Mutat. 2004 May;23(5):437-41 [15108274.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:250-6 [15251969.001]
  • [Cites] J Mol Diagn. 2004 Aug;6(3):236-42 [15269301.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5847-51 [1631067.001]
  • [Cites] Biotechniques. 1994 May;16(5):938-43 [8068351.001]
  • [Cites] J Clin Pathol. 1994 Dec;47(12):1082-4 [7876379.001]
  • [Cites] J Pathol. 1996 Jul;179(3):254-9 [8774479.001]
  • [Cites] Clin Chem. 1996 Sep;42(9):1382-90 [8787693.001]
  • [Cites] Diagn Mol Pathol. 1996 Dec;5(4):260-4 [8955617.001]
  • [Cites] Anal Biochem. 1997 May 1;247(2):394-403 [9177704.001]
  • [Cites] J Immunol Methods. 1997 Aug 7;206(1-2):11-9 [9328563.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):373-9 [9708798.001]
  • [Cites] Curr Opin Biotechnol. 1998 Dec;9(6):602-8 [9889145.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):83-95 [9916922.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9236-41 [10430926.001]
  • [Cites] Biotechniques. 2000 Jan;28(1):140-4, 146-7 [10649785.001]
  • [Cites] Gene. 2000 Aug 8;253(2):249-57 [10940563.001]
  • [Cites] Clin Chem. 2000 Dec;46(12):1929-38 [11106325.001]
  • [Cites] Genome Res. 2001 Jan;11(1):3-11 [11156611.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):105-10 [15681481.001]
  • (PMID = 16049314.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] ENG
  • [Grant] United States / PHS HHS / / P01-9467802; United States / PHS HHS / / P01-9483703; United States / PHS HHS / / R01-9485602
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC1867544
  •  go-up   go-down


41. Li HX, Li M, Li CL, Ma JH, Wang MR, Rao J, Pan QJ: ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study. Anal Quant Cytol Histol; 2010 Feb;32(1):45-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystoscopy with histologic diagnosis was used as the gold standard for diagnosis.
  • RESULTS: Of 169 inpatients, 135 cases had histologic diagnoses, including 93 cases of UC with primary tumors in 68 and recurrent tumors in 25, 26 cases of other urologic malignancies and 16 cases of benign urologic lesions.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701087.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-20
  •  go-up   go-down


42. Skvortsova TE, Rykova EY, Tamkovich SN, Bryzgunova OE, Starikov AV, Kuznetsova NP, Vlassov VV, Laktionov PP: Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer; 2006 May 22;94(10):1492-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation.
  • Tumour development is characterised by the increased circulating DNA (cirDNA) concentration and by tumour-related changes in blood plasma DNA.
  • Tumour development was shown to lead to significant changes in the distribution of cirDNA between cell-free and cell-surface-bound fractions.
  • Analysis of RARbeta2 and RASSF1A methylation in the total cirDNA provides 95% diagnostic coverage in breast cancer patients, 60% in patients with benign lesions, and is without false-positive results in healthy women.
  • Results of the study indicate that methylation-specific PCR of RARbeta2 and RASSF1A genes based on the total cirDNA combined with the quantitative analysis of cirDNA distribution between cell-bound and cell-free fractions in blood provide the sensitive and accurate detection and discrimination of malignant and benign breast tumours.
  • [MeSH-major] Breast Neoplasms / blood. DNA Methylation. DNA, Neoplasm / blood. DNA-Binding Proteins / genetics. Fibroadenoma / blood. Receptors, Retinoic Acid / genetics. Transcription Factors / genetics. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 2000 Apr;906:5-7 [10818586.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1075:191-6 [17108211.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):71-6 [11829433.001]
  • [Cites] Anticancer Drugs. 2002 Apr;13(4):353-7 [11984080.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5462-82 [12154408.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):149-52 [12455027.001]
  • [Cites] Nature. 2004 May 27;429(6990):457-63 [15164071.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:217-20 [15251963.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:221-7 [15251964.001]
  • [Cites] Anal Biochem. 1980 Mar 1;102(2):344-52 [6158890.001]
  • [Cites] J Clin Invest. 1985 Dec;76(6):2182-90 [3001145.001]
  • [Cites] Mol Biol (Mosk). 1988 Nov-Dec;22(6):1667-72 [3252155.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Nucleic Acids Res. 1999 Jun 1;27(11):2315-24 [10325420.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3956-63 [10339505.001]
  • [Cites] Histol Histopathol. 1999 Oct;14(4):1159-64 [10506932.001]
  • [Cites] Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(6-7):873-7 [15560075.001]
  • [Cites] Int J Cancer. 2000 Jul 20;89(4):389-94 [10956415.001]
  • (PMID = 16641902.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / HIC1 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta
  • [Other-IDs] NLM/ PMC2361269
  •  go-up   go-down


43. Valdman A, Häggarth L, Cheng L, Lopez-Beltran A, Montironi R, Ekman P, Egevad L: Expression of redox pathway enzymes in human prostatic tissue. Anal Quant Cytol Histol; 2009 Dec;31(6):367-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Another TMA containing benign prostatic tissue, atrophy, high grade prostatic intraepithelial neoplasia (HGPIN) and PCa from 40 patients was stained with all 3 antibodies.
  • RES ULTS: All 3 proteins showed similar expression patterns, with the highest immunoreactivity in HGPIN followed by atrophy, PCa and benign tissue.
  • TxnR2, Trx1 and Prdx2 were overexpressed in HGPIN and PCa compared with benign tissue (p < 0.001), and Trx1 and Prdx2 were also overexpressed in HGPIN compared with PCa (p < 0.001).

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698352.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TXN protein, human; 52500-60-4 / Thioredoxins; EC 1.11.1.15 / PRDX2 protein, human; EC 1.11.1.15 / Peroxiredoxins; EC 1.8.1.9 / TXNRD2 protein, human; EC 1.8.1.9 / Thioredoxin Reductase 2
  •  go-up   go-down


44. Hilfrich R, Hariri J: Prognostic relevance of human papillomavirus L1 capsid protein detection within mild and moderate dysplastic lesions of the cervix uteri in combination with p16 biomarker. Anal Quant Cytol Histol; 2008 Apr;30(2):78-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifty sections were derived from a benign group, 91 from low-grade (cervical intraepithelial neoplasia [CIN 1]) lesions and 50 from high-grade (CIN 2 and 3) lesions.

  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18561743.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Capsid Proteins; 0 / HPV L1 protein, Human papillomavirus; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Viral; 0 / P16 protein, human
  •  go-up   go-down


45. Piura B, Rabinovich A, Sinelnikov I, Delgado B: Tailgut cyst initially misdiagnosed as ovarian tumor. Arch Gynecol Obstet; 2005 Oct;272(4):301-3
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tailgut cyst initially misdiagnosed as ovarian tumor.
  • INTRODUCTION: Tailgut cyst (retrorectal cystic hamartoma) is an uncommon congenital lesion that arises from remnants of the embryonic post-anal gut.
  • It is usually benign and located in the retrorectal/presacral space.
  • The initial diagnosis was neoplasm of the right ovary.
  • Based on these histological findings, the final diagnosis was tailgut cyst.
  • CONCLUSION: Tailgut cyst is an uncommon entity that should be included in the differential diagnosis of retrorectal/presacral mass.
  • [MeSH-major] Cysts / diagnosis. Hamartoma / diagnosis. Peritoneal Neoplasms / diagnosis. Rectal Diseases / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Histocytochemistry. Humans. Hysterectomy. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16041543.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


46. Sheng SL, Bao SH, Huang G, Wang LM: Development of time-resolved immunofluorometric assays for vascular endothelial growth factor and application on plasma of patients with gastric tumours. Clin Exp Immunol; 2008 Mar;151(3):459-66
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plasma VEGF concentrations were measured by TR-IFMA in 92 healthy controls, in 36 benign stomach disease patients and in 92 gastric cancer patients before surgery.
  • VEGF levels were associated significantly with the presence of distant metastases, as well as invasion depth of the tumour and tumour stage, but not with tumour location, tumour histology, differentiation or the presence of lymph node metastases.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Stomach Neoplasms / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Aged. Aged, 80 and over. Enzyme-Linked Immunosorbent Assay. Female. Fluoroimmunoassay / methods. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Proteins / blood. Neoplasm Staging. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1998 Dec;34(13):2041-5 [10070308.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2187-90 [9815613.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Clin Chim Acta. 2006 Feb;364(1-2):12-21 [16139825.001]
  • [Cites] Clin Chim Acta. 2007 May 1;380(1-2):106-11 [17321510.001]
  • [Cites] Br J Cancer. 2000 Mar;82(5):1004-8 [10737380.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2898-905 [10850435.001]
  • [Cites] Circulation. 2000 Jul 11;102(2):185-90 [10889129.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):242-8 [11001067.001]
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):657-62 [11078612.001]
  • [Cites] Ann Surg. 2002 Jul;236(1):37-42 [12131083.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Nov;17(11):1165-9 [12453275.001]
  • [Cites] Clin Chem. 2003 Jan;49(1):97-103 [12507965.001]
  • [Cites] Cancer Lett. 2003 Mar 31;192(2):215-25 [12668286.001]
  • [Cites] Oncol Rep. 2004 Feb;11(2):435-9 [14719080.001]
  • [Cites] Steroids. 2004 Jul;69(7):461-71 [15246776.001]
  • [Cites] Clin Chem. 1983 Jan;29(1):65-8 [6336682.001]
  • [Cites] Nature. 1983 Jan 20;301(5897):258-60 [6337344.001]
  • [Cites] Anal Biochem. 1984 Mar;137(2):335-43 [6375455.001]
  • [Cites] Clin Chem. 1987 Nov;33(11):1994-9 [3119252.001]
  • [Cites] Clin Biochem. 1988 Jun;21(3):139-50 [3292080.001]
  • [Cites] Clin Chem. 1990 Aug;36(8 Pt 1):1497-502 [1696856.001]
  • [Cites] J Biol Chem. 1991 Jun 25;266(18):11947-54 [1711045.001]
  • [Cites] J Cell Biochem. 1991 Nov;47(3):211-8 [1791185.001]
  • [Cites] Mol Endocrinol. 1991 Dec;5(12):1806-14 [1791831.001]
  • [Cites] J Biol Chem. 1992 Jun 5;267(16):10931-4 [1375931.001]
  • [Cites] J Biol Chem. 1992 Dec 25;267(36):26031-7 [1464614.001]
  • [Cites] Am J Pathol. 1995 May;146(5):1029-39 [7538264.001]
  • [Cites] Pharmacol Ther. 1995 May;66(2):207-35 [7667396.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):663-8 [9012841.001]
  • [Cites] Ann Clin Biochem. 1997 May;34 ( Pt 3):276-80 [9158825.001]
  • [Cites] J Immunol Methods. 1998 Oct 1;219(1-2):45-55 [9831387.001]
  • [Cites] Ann Oncol. 1999 Aug;10(8):965-71 [10509160.001]
  • (PMID = 18234057.001).
  • [ISSN] 1365-2249
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2276956
  •  go-up   go-down


47. Compérat E, Egevad L, Camparo P, Roupret M, Vaessen C, Valdman A, Jonmarker S, Capron F, Cussenot O, Charlotte F: Clinical significance of intratumoral CD8+ regulatory T cells in prostate carcinoma. Anal Quant Cytol Histol; 2010 Feb;32(1):39-44
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In tumor cores, Foxp3 and CD8 counts correlated (p = 0.012).
  • CONCLUSION: Treg cells were more common in cancer than in benign prostatic tissue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701086.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


48. Berman DM, Wincovitch S, Garfield S, Romeo MJ: Grading melanocytic dysplasia in paraffin wax embedded tissue by the nucleic acid index. J Clin Pathol; 2005 Nov;58(11):1206-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although nucleic acid derangements are the hallmark of melanocytic dysplasia, the gold standard for its diagnosis remains the microscopic evaluation of haematoxylin and eosin stained slides.
  • RESULTS: When applied to benign naevi, dysplastic naevi, and melanoma, a very strong significant association was seen between lower NAI and malignant potential (p < 0.0001).
  • Interestingly, the NAI for dysplastic naevi is between that of melanoma and most benign naevi, consistent with their intermediate biological behaviour and histological appearance.
  • CONCLUSION: By providing a quantitative measure for melanocytic neoplasia, the NAI may improve the diagnosis of melanocytic lesions and the selection of treatment.
  • [MeSH-major] DNA, Neoplasm / analysis. Dysplastic Nevus Syndrome / diagnosis. Melanoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Image Processing, Computer-Assisted / methods. Melanocytes / pathology. Microscopy, Confocal / methods. Mitotic Index. Nevus, Pigmented / diagnosis. Nevus, Pigmented / genetics. Nevus, Pigmented / pathology. Paraffin Embedding. RNA, Neoplasm / analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neuropathol. 1998 Nov;96(5):487-94 [9829812.001]
  • [Cites] Clin Cancer Res. 1996 Feb;2(2):419-26 [9816186.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):19-20 [12447372.001]
  • [Cites] Am J Dermatopathol. 2003 Jun;25(3):190-7 [12775980.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3081-6 [12789284.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):764-71 [12920220.001]
  • [Cites] Anal Quant Cytol Histol. 2003 Oct;25(5):243-53 [14603721.001]
  • [Cites] Melanoma Res. 2003 Dec;13(6):581-6 [14646621.001]
  • [Cites] Br J Dermatol. 2004 Feb;150(2):179-85 [14996086.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):342-8 [15009715.001]
  • [Cites] J Am Acad Dermatol. 2004 Jul;51(1 Suppl):S65-9 [15243517.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121 Suppl:S3-32 [15298148.001]
  • [Cites] Lancet. 1977 Apr 16;1(8016):864-5 [67377.001]
  • [Cites] Arch Dermatol. 1978 May;114(5):732-8 [646394.001]
  • [Cites] Cancer Res. 1978 Jul;38(7):1893-8 [77721.001]
  • [Cites] Microsc Acta. 1981 Jan;84(1):37-42 [6163065.001]
  • [Cites] Cytometry. 1982 Jan;2(4):212-8 [6173180.001]
  • [Cites] Cytometry. 1982 Jul;3(1):28-35 [6180873.001]
  • [Cites] Am J Clin Pathol. 1985 Jun;83(6):722-5 [2408462.001]
  • [Cites] J Am Acad Dermatol. 1989 Oct;21(4 Pt 1):773-80 [2808793.001]
  • [Cites] J Cutan Pathol. 1993 Apr;20(2):121-5 [8320355.001]
  • [Cites] Kurume Med J. 1994;41(1):1-13 [7933912.001]
  • [Cites] Hum Pathol. 1996 Jun;27(6):528-31 [8666360.001]
  • [Cites] Cytometry. 1997 Feb 1;27(2):99-105 [9012376.001]
  • [Cites] Histochem Cell Biol. 1997 Apr;107(4):267-78 [9151109.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1370-7 [10717619.001]
  • (PMID = 16254113.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC1770753
  •  go-up   go-down


49. Zon G, Barker MA, Kaur P, Groshen S, Jones LW, Imam SA, Boyd VL: Formamide as a denaturant for bisulfite conversion of genomic DNA: Bisulfite sequencing of the GSTPi and RARbeta2 genes of 43 formalin-fixed paraffin-embedded prostate cancer specimens. Anal Biochem; 2009 Sep 15;392(2):117-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Detection of methylated GSTPi and RARbeta2 genes was significantly associated with primary prostate cancer as compared with the benign prostate (Fisher's exact test, P < 0.001).
  • [MeSH-major] DNA, Neoplasm / chemistry. Formamides / pharmacology. Genome, Human. Glutathione S-Transferase pi / genetics. Prostatic Neoplasms / genetics. Receptors, Retinoic Acid / genetics. Sequence Analysis, DNA / methods
  • [MeSH-minor] Base Sequence. Biomarkers, Tumor / genetics. Biopsy. DNA Methylation. Formaldehyde. Humans. Male. Molecular Sequence Data. Nucleic Acid Denaturation / drug effects. Paraffin Embedding. Sulfites

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • Hazardous Substances Data Bank. FORMAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19505431.001).
  • [ISSN] 1096-0309
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Formamides; 0 / Receptors, Retinoic Acid; 0 / Sulfites; 0 / retinoic acid receptor beta; 1HG84L3525 / Formaldehyde; 4781T907ZS / formamide; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi
  •  go-up   go-down


50. Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N: Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol; 2008;9:76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, the expression of five miRNA genes (let-7a, miR-10b, miR-16, miR-21 and miR-26b) and three small nucleolar RNA genes (RNU19, RNU48 and Z30) was examined across malignant, benign and normal breast tissues to determine the most appropriate normalisation strategy.
  • [MeSH-minor] Female. Gene Silencing. Genes, Neoplasm. Humans. Polymerase Chain Reaction / standards. RNA, Small Nuclear / genetics. Reference Standards

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2005 Dec 15;14(24):3813-21 [16239240.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] Nucleic Acids Res. 2006;34(2):e9 [16434699.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Apr 28;343(1):85-9 [16529715.001]
  • [Cites] J Urol. 2006 May;175(5):1915-20 [16600798.001]
  • [Cites] Mol Cancer. 2006;5:24 [16784538.001]
  • [Cites] Oncogene. 2006 Oct 9;25(46):6188-96 [17028598.001]
  • [Cites] Cell. 2006 Nov 17;127(4):679-95 [17110329.001]
  • [Cites] Mol Cell Biol. 2007 Mar;27(5):1859-67 [17194750.001]
  • [Cites] Am J Obstet Gynecol. 2007 Mar;196(3):261.e1-6 [17346547.001]
  • [Cites] Nat Protoc. 2006;1(3):1559-82 [17406449.001]
  • [Cites] BMC Genomics. 2007;8:166 [17565689.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Nov 23;363(3):542-6 [17889832.001]
  • [Cites] Nature. 2007 Oct 11;449(7163):682-8 [17898713.001]
  • [Cites] Nature. 2008 Jan 10;451(7175):147-52 [18185580.001]
  • [Cites] BMC Mol Biol. 2007;8:107 [18042273.001]
  • [Cites] Nat Cell Biol. 2008 Feb;10(2):202-10 [18193036.001]
  • [Cites] Breast Cancer Res. 2007;9(6):R76 [17980029.001]
  • [Cites] Hepatology. 2008 Mar;47(3):897-907 [18176954.001]
  • [Cites] RNA. 2008 May;14(5):844-52 [18375788.001]
  • [Cites] J Biol Chem. 2000 May 5;275(18):13967-73 [10788523.001]
  • [Cites] J Mol Endocrinol. 2000 Oct;25(2):169-93 [11013345.001]
  • [Cites] J Biochem Biophys Methods. 2000 Nov 20;46(1-2):69-81 [11086195.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14311-6 [11106375.001]
  • [Cites] EMBO Rep. 2001 Nov;2(11):986-91 [11713189.001]
  • [Cites] Hum Mol Genet. 2001 Nov 1;10(23):2687-700 [11726556.001]
  • [Cites] Nucleic Acids Res. 2002 Feb 15;30(4):894-902 [11842100.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Mol Cell Biol. 2002 Oct;22(19):6663-8 [12215523.001]
  • [Cites] Anal Biochem. 2002 Oct 15;309(2):293-300 [12413463.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Cancer Lett. 2003 Mar 20;192(1):1-17 [12637148.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Bioessays. 2003 Oct;25(10):930-9 [14505360.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D109-11 [14681370.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Genome Biol. 2004;5(3):R13 [15003116.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9740-4 [15210942.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5245-50 [15289330.001]
  • [Cites] J Biomol Tech. 2004 Sep;15(3):155-66 [15331581.001]
  • [Cites] Genome Biol. 2004;5(9):R68 [15345052.001]
  • [Cites] In Vitro Cell Dev Biol. 1987 Aug;23(8):585-90 [3114226.001]
  • [Cites] Cancer Res. 1987 Nov 1;47(21):5616-9 [3664468.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Mol Cell Biol. 1996 Apr;16(4):1391-400 [8657112.001]
  • [Cites] BMC Dev Biol. 2005;5:27 [16324220.001]
  • [Cites] Cell. 1997 May 30;89(5):799-809 [9182768.001]
  • [Cites] Nucleic Acids Res. 1998 Apr 1;26(7):1576-87 [9512526.001]
  • [Cites] RNA. 1998 Apr;4(4):445-54 [9630250.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):6906-17 [10490628.001]
  • [Cites] Anal Biochem. 2004 Dec 1;335(1):1-9 [15519565.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6029-33 [16024602.001]
  • [Cites] Biotechniques. 2005 Jul;39(1):75-85 [16060372.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7376-83 [16243810.001]
  • [Cites] RNA. 2005 Nov;11(11):1737-44 [16244135.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4 [16381832.001]
  • (PMID = 18718003.001).
  • [ISSN] 1471-2199
  • [Journal-full-title] BMC molecular biology
  • [ISO-abbreviation] BMC Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Small Nuclear
  • [Other-IDs] NLM/ PMC2533012
  •  go-up   go-down


51. Speake D, Lees N, McMahon RF, Hill J: Who should be followed up after transanal endoscopic resection of rectal tumours? Colorectal Dis; 2008 May;10(4):330-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of the 117 procedures performed, 80 were for benign disease and 37 for malignancy.
  • Within the benign group 39 (49%) resections were intact with clear surgical resection margins and yielded zero recurrences; 22 (27%) resections were macroscopically intact with microscopically involved surgical resection margin and yielded two recurrences; and 19 (24%) resections were piecemeal and yielded eight recurrences.
  • CONCLUSION: For benign rectal neoplasms, resection of an intact specimen with histologically clear surgical resection margins was associated with no observed mucosal recurrence.
  • [MeSH-major] Adenoma. Carcinoma. Endoscopy, Gastrointestinal / methods. Microsurgery / methods. Neoplasm Recurrence, Local / prevention & control. Rectal Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Case-Control Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18190616.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


52. Røkke O, Faerden AE, Øvrebø K: [Transanal endoscopic microsurgery for tumours in rectum]. Tidsskr Nor Laegeforen; 2007 Nov 15;127(22):2954-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Rectal tumors up to 25 cm from the anal verge may be resected by transanal endoscopic microsurgery (TEM).
  • TEM is suitable for resection of benign adenomas, but can also be used for selected malignant tumours.
  • TEM is especially suitable to resect benign adenomas, and may also have a place as primary treatment of selected malignant tumours in Norway.
  • [MeSH-minor] Humans. Neoplasm Recurrence, Local. Postoperative Complications / diagnosis. Proctoscopes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18026244.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 50
  •  go-up   go-down


53. Fenech DS, Takahashi T, Liu M, Spencer L, Swallow CJ, Cohen Z, Macrae HM, McLeod RS: Function and quality of life after transanal excision of rectal polyps and cancers. Dis Colon Rectum; 2007 May;50(5):598-603
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: All patients having a transanal excision at the Mount Sinai Hospital from 1989 to 2002 were included if the indication for surgery was a benign or malignant neoplasm.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Biopsy. Female. Humans. Male. Middle Aged. Statistics, Nonparametric. Surveys and Questionnaires. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309002.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Chesnokova V, Zonis S, Rubinek T, Yu R, Ben-Shlomo A, Kovacs K, Wawrowsky K, Melmed S: Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res; 2007 Nov 1;67(21):10564-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth.
  • Understanding factors subserving pituitary cell proliferation enables understanding mechanisms underlying uniquely benign pituitary tumors.
  • Pituitary tumor-transforming gene (Pttg) deletion results in pituitary hypoplasia, low pituitary cell proliferation rates, and rescue of pituitary tumor development in Rb(+/-) mice.
  • As cell proliferation assessed by bromodeoxyuridine incorporation was higher in Rb(+/-)Pttg(-/-)p21(-/-) relative to Rb(+/-)Pttg(-/-) pituitary glands, p21-dependent senescence provoked by Pttg deletion may underlie pituitary hypoplasia and decreased tumor development in Rb(+/-)Pttg(-/-) mice.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] Cell. 1995 May 5;81(3):323-30 [7736585.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Nature. 1998 Sep 10;395(6698):125-6 [9744268.001]
  • [Cites] EMBO J. 1999 Jan 4;18(1):22-7 [9878046.001]
  • [Cites] Prog Mol Subcell Biol. 1998;20:43-71 [9928526.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):761-7 [10022450.001]
  • [Cites] Mech Dev. 1999 Mar;81(1-2):23-35 [10330482.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):7011-9 [10490638.001]
  • [Cites] Oncogene. 1999 Sep 23;18(39):5473-6 [10498901.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):51100-6 [15456744.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2899-908 [15838523.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2371-9 [15919720.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8747-53 [16204044.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Oct;27(5):241-52 [16447816.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):25-36 [17189716.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):749-59 [17071631.001]
  • [Cites] Endocr Rev. 2007 Apr;28(2):165-86 [17325339.001]
  • [Cites] Oncogene. 2007 Aug 16;26(38):5596-605 [17353909.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C1082-92 [17626243.001]
  • [Cites] Nat Cell Biol. 2001 Mar;3(3):245-52 [11231573.001]
  • [Cites] Oncogene. 2001 Feb 22;20(8):962-71 [11314031.001]
  • [Cites] Cell. 2001 May 18;105(4):445-57 [11371342.001]
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):1870-9 [11682618.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S27-31 [11684439.001]
  • [Cites] Curr Opin Cell Biol. 2001 Dec;13(6):748-53 [11698192.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1317-21 [10546001.001]
  • [Cites] Nat Cell Biol. 2000 Mar;2(3):148-55 [10707085.001]
  • [Cites] Pituitary. 1999 May;1(3-4):169-79 [11081195.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36502-5 [11013229.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):867-74 [11158059.001]
  • [Cites] Cell. 2002 May 3;109(3):335-46 [12015983.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10305-9 [12124396.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):647-56 [12209154.001]
  • [Cites] Minerva Endocrinol. 2002 Dec;27(4):277-85 [12511850.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3428-32 [12626748.001]
  • [Cites] Neurosurg Clin N Am. 2003 Jan;14(1):25-39, vi [12690977.001]
  • [Cites] Cancer. 2003 Jun 1;97(11):2814-21 [12767095.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):4991-8 [12960092.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):160-8 [14722605.001]
  • [Cites] Oncogene. 2004 Mar 15;23(11):1998-2008 [15021887.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3296-307 [15021915.001]
  • [Cites] Mol Cell. 2004 May 21;14(4):501-13 [15149599.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):792-804 [15459660.001]
  • [Cites] J Clin Invest. 1982 Nov;70(5):965-77 [6290540.001]
  • [Cites] J Cell Biol. 1997 Jan 13;136(1):1-4 [9026502.001]
  • (PMID = 17975001.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA075979-09; United States / NCI NIH HHS / CA / R01 CA075979; United States / NCI NIH HHS / CA / CA75979; United States / NCI NIH HHS / CA / R01 CA075979-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn1a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Neoplasm Proteins; 0 / Retinoblastoma Protein; 0 / Securin; 0 / Sp1 Transcription Factor; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS121885; NLM/ PMC2770267
  •  go-up   go-down


55. Bretagnol F, Merrie A, George B, Warren BF, Mortensen NJ: Local excision of rectal tumours by transanal endoscopic microsurgery. Br J Surg; 2007 May;94(5):627-33
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Transanal endoscopic microsurgery (TEM) allows locally complete excision of rectal tumours and provides an alternative to conventional surgery for benign tumours.
  • The median tumour distance from the anal verge was 8 (range 1-16) cm.
  • Histological examination of carcinomas revealed pathological tumour (pT) stage 1 in 31 patients, pT2 in 17 and pT3 in four.
  • CONCLUSION: TEM is an appropriate surgical treatment option for benign rectal tumours.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Intraoperative Complications / etiology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Patient Selection. Salvage Therapy. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Surg. 2007 Sep;94(9):1179; author reply 1179 [17701963.001]
  • (PMID = 17335125.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


56. Kronenwett U, Huwendiek S, Castro J, Ried T, Auer G: Characterisation of breast fine-needle aspiration biopsies by centrosome aberrations and genomic instability. Br J Cancer; 2005 Jan 31;92(2):389-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign lesions did not show any centrosome aberrations.
  • Our results indicate the percentage of cells with centrosome aberrations as being sufficient to divide the investigated tumours into three significantly different groups: benign lesions with no centrosomal aberrations, and two malignant tumour types with mean values of 2.1 and 9.6% of centrosomal defects, respectively.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Centrosome / pathology. DNA, Neoplasm / analysis. Genomic Instability

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Quant Cytol. 1980 Sep;2(3):161-5 [6252802.001]
  • [Cites] Acta Radiol Ther Phys Biol. 1968 Aug;7(4):241-62 [4179434.001]
  • [Cites] Cancer. 1988 Jul 15;62(2):331-41 [3383134.001]
  • [Cites] Cancer. 1988 Aug 1;62(3):521-30 [3390793.001]
  • [Cites] Hum Pathol. 1989 Jun;20(6):518-27 [2470665.001]
  • [Cites] Cell. 1991 May 31;65(5):825-36 [1840506.001]
  • [Cites] Radiol Clin North Am. 1992 Jan;30(1):167-85 [1732925.001]
  • [Cites] Nature. 1992 Mar 5;356(6364):80-3 [1538786.001]
  • [Cites] Eur J Surg Oncol. 1992 Apr;18(2):108-11 [1582502.001]
  • [Cites] Curr Opin Cell Biol. 1993 Feb;5(1):105-15 [8448021.001]
  • [Cites] Hum Pathol. 1993 Dec;24(12):1348-53 [8276382.001]
  • [Cites] Annu Rev Biochem. 1994;63:639-74 [7979251.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5415-23 [7585611.001]
  • [Cites] Oncology (Williston Park). 1996 Jun;10(6):867-82, 887; discussion 887-90 [8823802.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2765-80 [9205089.001]
  • [Cites] Br J Biomed Sci. 1997 Jun;54(2):140-8 [9231461.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2950-5 [9501196.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):223-4 [9521314.001]
  • [Cites] Diagn Cytopathol. 1998 Jun;18(6):462-7 [9626523.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3974-85 [9731511.001]
  • [Cites] Cell Motil Cytoskeleton. 1998;41(4):281-8 [9858153.001]
  • [Cites] Nat Cell Biol. 1999 Jun;1(2):88-93 [10559879.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1941-51 [10595924.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Feb;27(2):183-90 [10612807.001]
  • [Cites] Curr Opin Cell Biol. 2000 Feb;12(1):113-8 [10679351.001]
  • [Cites] Curr Opin Oncol. 2000 Jan;12(1):82-8 [10687734.001]
  • [Cites] Curr Top Dev Biol. 2000;49:267-89 [11005023.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):279-84 [11301343.001]
  • [Cites] Genes Dev. 2001 May 15;15(10):1167-81 [11358861.001]
  • [Cites] Cell. 2001 May 18;105(4):417-20 [11371338.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1978-83 [11830638.001]
  • [Cites] Int J Oncol. 2002 Jun;20(6):1161-5 [12011993.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1398-404 [12649205.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):904-9 [14871819.001]
  • [Cites] Cancer Res. 1984 Jan;44(1):394-6 [6690053.001]
  • (PMID = 15558069.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2361862
  •  go-up   go-down


57. Jeong WK, Park JW, Choi HS, Chang HJ, Jeong SY: Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center. Surg Endosc; 2009 Nov;23(11):2575-9
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Transanal endoscopic microsurgery (TEM) is a minimally invasive alternative to transanal excision, enabling complete local excision of selected benign or malignant rectal tumors.
  • METHODS: From November 2001 to October 2007, 45 patients underwent TEM for excision of adenoma (13 patients), carcinoid tumor (6 patients), and carcinoma (26 patients).
  • RESULTS: The median tumor distance from the anal verge was 7 cm (range, 3-15 cm), and the median tumor size was 17 mm (range, 2-60 mm).
  • Histologic examination of the carcinomas showed pathologic tumor (pT) stage 0 (ypT0) in 2 patients, pT1 in 17 patients (including ypT1 in 1 patient), pT2 in 6 patients, and pT3 in 1 patient.
  • CONCLUSIONS: The TEM procedure is a safe and appropriate surgical treatment option for benign rectal tumors.
  • [MeSH-major] Anal Canal / surgery. Microsurgery / methods. Neoplasm Recurrence, Local / pathology. Proctoscopy / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / mortality. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Cancer Care Facilities. Carcinoid Tumor / mortality. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Korea. Male. Middle Aged. Minimally Invasive Surgical Procedures / adverse effects. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Patient Selection. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Reoperation. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19347399.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


58. Schulte T, Kahlke V: [Mass of the pelvis minor--the coloproctological point of view]. Ther Umsch; 2007 Jul;64(7):389-94
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It contains the pelvic organs like the inner genital organs of women, the urinary bladder the rectum and parts of the anus.
  • The rectum is the origin of benign and malign tumors.
  • Most frequently you find under these tumors the benign adenoma and hamartoma and the malign like the rectal and anal cancer.
  • The further diagnostic work up and following therapy relates to the histology and the anatomical location of the tumor.
  • [MeSH-major] Anus Neoplasms. Pelvic Neoplasms. Rectal Neoplasms
  • [MeSH-minor] Adult. Colonoscopy. Combined Modality Therapy. Diagnosis, Differential. Endosonography. Humans. Middle Aged. Neoplasm Staging. Postoperative Care. Proctoscopy. Rectum / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17948756.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


59. Chesnokova V, Melmed S: Pituitary senescence: the evolving role of Pttg. Mol Cell Endocrinol; 2010 Sep 15;326(1-2):55-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the high prevalence of pituitary adenomas they are invariably benign, indicative of unique intrinsic mechanisms controlling pituitary cell proliferation.
  • Cellular senescence is characterized by a largely irreversible cell cycle arrest and constitutes a strong anti-proliferative response, which can be triggered by DNA damage, chromosomal instability and aneuploidy, loss of tumor suppressive signaling or oncogene activation.
  • Here we discuss prospective mechanisms underlying senescence-associated molecular pathways activated in benign pituitary adenomas.
  • Both deletion and over-expression of pituitary tumor transforming gene (Pttg) promote chromosomal instability and aneuploidy.
  • Pttg deletion abrogates tumor development by activating p53/p21-dependent senescence pathways.
  • Pituitary p21 may therefore safeguard against further chromosomal instability by constraining pituitary tumor growth.
  • These observations point to senescence as a target for effective therapy for both tumor silencing and growth restraint towards development of pituitary malignancy.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ireland Ltd. All rights reserved.
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):1870-9 [11682618.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S27-31 [11684439.001]
  • [Cites] J Clin Invest. 2001 Dec;108(12):1729-33 [11748253.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):503-11 [11850775.001]
  • [Cites] Cell. 2002 May 3;109(3):335-46 [12015983.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3428-32 [12626748.001]
  • [Cites] Front Neuroendocrinol. 2003 Apr;24(2):94-127 [12763000.001]
  • [Cites] Endocr Relat Cancer. 2003 Jun;10(2):323-30 [12790793.001]
  • [Cites] Cell. 2003 Jun 13;113(6):703-16 [12809602.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):4991-8 [12960092.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):160-8 [14722605.001]
  • [Cites] Nature. 1989 Aug 31;340(6236):692-6 [2549426.001]
  • [Cites] Nature. 1990 May 31;345(6274):458-60 [2342578.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] Cell. 1997 Mar 7;88(5):593-602 [9054499.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Mol Endocrinol. 1999 Jan;13(1):156-66 [9892021.001]
  • [Cites] Prog Mol Subcell Biol. 1998;20:43-71 [9928526.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):1002-7 [9927683.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1317-21 [10546001.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):761-7 [10022450.001]
  • [Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]
  • [Cites] Exp Cell Res. 1961 Dec;25:585-621 [13905658.001]
  • [Cites] Ann Diagn Pathol. 2005 Feb;9(1):6-10 [15692944.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • [Cites] Oncogene. 2005 Jul 14;24(30):4861-6 [15897900.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):660-5 [16079837.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] Science. 2005 Aug 5;309(5736):886-7 [16081723.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2371-9 [15919720.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8747-53 [16204044.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Oct;27(5):241-52 [16447816.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):707-16 [16954426.001]
  • [Cites] N Engl J Med. 2006 Sep 7;355(10):1037-46 [16957149.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):633-7 [17136093.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C1082-92 [17626243.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10564-72 [17975001.001]
  • [Cites] Endocrinology. 2007 Dec;148(12):6019-25 [17872367.001]
  • [Cites] Cell Death Differ. 2008 Jan;15(1):202-12 [17962814.001]
  • [Cites] Trends Genet. 2008 Feb;24(2):77-85 [18192065.001]
  • [Cites] Science. 2008 Mar 7;319(5868):1352-5 [18323444.001]
  • [Cites] Cell. 2008 Jun 13;133(6):958-61 [18555773.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17498-503 [18981426.001]
  • [Cites] Pituitary. 2009;12(1):40-50 [18270844.001]
  • [Cites] Nat Rev Cancer. 2009 Feb;9(2):81-94 [19132009.001]
  • [Cites] Cell Cycle. 2009 Mar 1;8(5):677-8 [19223763.001]
  • [Cites] Clin Endocrinol (Oxf). 2010 Mar;72(3):377-82 [19650784.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Dec;2(12):681-93 [17143315.001]
  • [Cites] Nature. 2006 Dec 21;444(7122):1038-43 [17183314.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19842-7 [17170138.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):749-59 [17071631.001]
  • [Cites] Endocr Rev. 2007 Apr;28(2):165-86 [17325339.001]
  • [Cites] Cell. 2007 Jul 27;130(2):223-33 [17662938.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36502-5 [11013229.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):867-74 [11158059.001]
  • (PMID = 20153804.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA075979-11A1; United States / NCI NIH HHS / CA / R01 CA075979; United States / NCI NIH HHS / CA / R01 CA075979-11A1
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Securin; 0 / pituitary tumor-transforming protein 1, human
  • [Other-IDs] NLM/ NIHMS185500; NLM/ PMC2906651
  •  go-up   go-down


60. Tytherleigh MG, Birtle AJ, Cohen CE, Glynne-Jones R, Livingstone J, Gilbert J: Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour. Surgeon; 2006 Dec;4(6):378-83
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour.
  • BACKGROUND: The Buschke-Löwenstein tumour (BLT) or giant condyloma acuminata is a rare disease which affects the anogenital region.
  • Although histologically benign, it behaves in a malignant fashion, infiltrating the surrounding tissues.
  • The morbidity and mortality from this tumour is high, as is the risk of recurrence following treatment.
  • It lies on the continuum between the benign condylomata acuminata and squamous cell carcinoma.
  • Chemoradiation remains the mainstay of treatment for anal cancers but has not been routinely employed in the management of the BLT without squamous cell carcinoma transformation.
  • CONCLUSION: Pre-operative chemoradiation has proved to be useful in management for histologically proven benign BLT
  • [MeSH-minor] Abdominal Neoplasms / secondary. Abdominal Neoplasms / therapy. Adult. Anus Neoplasms / secondary. Anus Neoplasms / therapy. Carcinoma in Situ / pathology. Carcinoma in Situ / therapy. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Fatal Outcome. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Rectal Neoplasms / secondary. Rectal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152203.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


61. Bearzi I, Mandolesi A, Arduini F, Costagliola A, Ranaldi R: Gastrointestinal stromal tumor. A study of 158 cases: clinicopathological features and prognostic factors. Anal Quant Cytol Histol; 2006 Jun;28(3):137-47
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumor. A study of 158 cases: clinicopathological features and prognostic factors.
  • RESULTS: Most of the GISTs had a benign behavior.
  • CONCLUSION: Mitotic activity is important in predicting the outcome of patients with high risk GIST who present at diagnosis without dissemination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16786723.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


62. Yu N, Kozlowski JM, Park II, Chen L, Zhang Q, Xu D, Doll JA, Crawford SE, Brendler CB, Lee C: Overexpression of transforming growth factor β1 in malignant prostate cells is partly caused by a runaway of TGF-β1 auto-induction mediated through a defective recruitment of protein phosphatase 2A by TGF-β type I receptor. Urology; 2010 Dec;76(6):1519.e8-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Malignant (PC3, DU145) and benign (RWPE1, BPH1) prostate epithelial cells were used.
  • RESULTS: Basal levels of TGF-β1 in malignant cells were significantly higher than those in benign cells.
  • Blockade of TGF-β signaling resulted in a significant decrease in TGF-β1 expression in malignant cells, but not in benign cells.
  • Upon TGF-β1 treatment (10 ng/mL), TGF-β1 expression was increased in malignant cells, but not in benign cells.
  • This differential TGF-β1 auto-induction between benign and malignant cells correlated with differential activation of extracellular signal-regulated kinase (ERK).
  • Following TGF-β1 treatment, the activity of serine/threonine phosphatase and recruitment of PP2A-Bα by TβRI increased in benign cells, but not in malignant cells.
  • Inhibition of PP2A in benign cells resulted in an increase in ERK activation and in TGF-β1 auto-induction after TGF-β1 (10 ng/mL) treatment.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] EMBO J. 2007 Sep 5;26(17):3957-67 [17673906.001]
  • [Cites] EMBO Rep. 2008 Oct;9(10):990-7 [18704116.001]
  • [Cites] Int J Oncol. 2007 Feb;30(2):499-507 [17203233.001]
  • [Cites] Am J Pathol. 2006 Oct;169(4):1282-93 [17003485.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Apr;290(4):C1100-8 [16371439.001]
  • [Cites] Respir Res. 2006;7:2 [16390551.001]
  • [Cites] Cell Tissue Res. 2005 Oct;322(1):43-52 [15909166.001]
  • [Cites] Oncogene. 2000 Sep 14;19(39):4531-41 [11002426.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):111-6 [11237527.001]
  • [Cites] J Immunol. 2002 Oct 1;169(7):3485-91 [12244137.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] Anal Biochem. 2004 Apr 1;327(1):45-54 [15033509.001]
  • [Cites] Mol Cell. 2004 Jul 23;15(2):170-1 [15260968.001]
  • [Cites] J Biol Chem. 1988 Jun 5;263(16):7741-6 [3259578.001]
  • [Cites] Mol Cell Biol. 1990 Apr;10(4):1492-7 [2108318.001]
  • [Cites] FEBS Lett. 1990 May 21;264(2):187-92 [2162782.001]
  • [Cites] Am J Respir Cell Mol Biol. 1993 Apr;8(4):417-24 [8476635.001]
  • [Cites] Science. 1995 Jun 30;268(5219):1902-6 [7604263.001]
  • [Cites] Ann Surg. 1995 Aug;222(2):146-54 [7639582.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1996 Dec;37(13):2778-82 [8977496.001]
  • [Cites] Br J Urol. 1998 Mar;81(3):403-5 [9523660.001]
  • [Cites] Mol Cell Biol. 1998 Nov;18(11):6595-604 [9774674.001]
  • [Cites] Hepatology. 1999 May;29(5):1418-24 [10216124.001]
  • [Cites] Prostate. 1999 Jun 1;39(4):285-90 [10344218.001]
  • [Cites] J Immunol. 2008 Mar 1;180(5):2757-61 [18292494.001]
  • [Cites] FASEB J. 2008 Apr;22(4):954-65 [18039929.001]
  • [Cites] Cell. 2008 Jul 25;134(2):215-30 [18662538.001]
  • [Cites] Kidney Int. 2005 Sep;68(3):972-84 [16105028.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3557-67 [19447876.001]
  • [Cites] Exp Cell Res. 2007 Sep 10;313(15):3167-74 [17643425.001]
  • (PMID = 21030067.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090386-06A2; United States / NCI NIH HHS / CA / P50 CA090386; United States / NCI NIH HHS / CA / P50 CA090386-06A2; United States / NCI NIH HHS / CA / P50CA90386
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / PPP2R2A protein, human; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; EC 2.7.1.11 / TGF-beta type I receptor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.1.3.16 / Protein Phosphatase 2
  • [Other-IDs] NLM/ NIHMS194313; NLM/ PMC2997920
  •  go-up   go-down


63. Yegingil H, Shih WY, Shih WH: Probing model tumor interfacial properties using piezoelectric cantilevers. Rev Sci Instrum; 2010 Sep;81(9):095104
Hazardous Substances Data Bank. ZIRCONIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probing model tumor interfacial properties using piezoelectric cantilevers.
  • Invasive malignant breast cancers are typically branchy and benign breast tumors are typically smooth.
  • It is of interest to characterize tumor branchiness (roughness) to differentiate invasive malignant breast cancer from noninvasive ones.
  • In this study, we examined the shear modulus (G) to elastic modulus (E) ratio, G/E, as a quantity to describe model tumor interfacial roughness using a piezoelectric cantilever capable of measuring both tissue elastic modulus and tissue shear modulus.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Lead, elemental .
  • Hazardous Substances Data Bank. TITANIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ultrasonics. 2000 Mar;38(1-8):400-4 [10829696.001]
  • [Cites] Arch Surg. 2001 Feb;136(2):204-8 [11177142.001]
  • [Cites] J Digit Imaging. 2002;15 Suppl 1:224-7 [12105735.001]
  • [Cites] Ultrasound Med Biol. 2003 Jun;29(6):813-23 [12837497.001]
  • [Cites] Annu Rev Biomed Eng. 2003;5:57-78 [12704084.001]
  • [Cites] IEEE Trans Med Imaging. 2004 Jan;23(1):111-21 [14719692.001]
  • [Cites] Radiology. 1999 Jun;211(3):845-50 [10352614.001]
  • [Cites] Phys Med Biol. 2006 Jan 21;51(2):425-41 [16394348.001]
  • [Cites] Physiol Meas. 2005 Jun;26(3):215-28 [15798297.001]
  • [Cites] Phys Med Biol. 2007 Mar 21;52(6):1565-76 [17327649.001]
  • [Cites] Med Eng Phys. 2008 Oct;30(8):1013-9 [18495518.001]
  • [Cites] Rev Sci Instrum. 2007 Nov;78(11):115101 [18052498.001]
  • [Cites] Med Image Anal. 2007 Aug;11(4):361-73 [17509927.001]
  • (PMID = 20887005.001).
  • [ISSN] 1089-7623
  • [Journal-full-title] The Review of scientific instruments
  • [ISO-abbreviation] Rev Sci Instrum
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB000720; United States / NIBIB NIH HHS / EB / 1 R01 EB000720
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aluminum Silicates; 12626-81-2 / lead titanate zirconate; 1302-87-0 / clay; 2P299V784P / Lead; C6V6S92N3C / Zirconium; D1JT611TNE / Titanium
  • [Other-IDs] NLM/ PMC2955722
  •  go-up   go-down


64. Chesnokova V, Zonis S, Kovacs K, Ben-Shlomo A, Wawrowsky K, Bannykh S, Melmed S: p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci U S A; 2008 Nov 11;105(45):17498-503
SciCrunch. The Antibody Registry: Reagent: Antibodies .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p21(Cip1) restrains pituitary tumor growth.
  • As commonly encountered, pituitary adenomas are invariably benign.
  • Pituitary tumor transforming gene (Pttg) deletion results in pituitary p21 induction and abrogates tumor development in Rb(+/-)Pttg(-/-) mice. p21 disruption restores attenuated Rb(+/-)Pttg(-/-) pituitary proliferation rates and enables high penetrance of pituitary, but not thyroid, tumor growth in triple mutant animals (88% of Rb(+/-) and 72% of Rb(+/-)Pttg(-/-)p21(-/-) vs. 30% of Rb(+/-)Pttg(-/-) mice developed pituitary tumors, P < 0.001).
  • Intranuclear p21 accumulates in Pttg-null aneuploid GH-secreting cells, and GH(3) rat pituitary tumor cells overexpressing PTTG also exhibited increased levels of mRNA for both p21 (18-fold, P < 0.01) and ATM (9-fold, P < 0.01).
  • Aneuploid pituitary cell p21 may constrain pituitary tumor growth, thus accounting for the very low incidence of pituitary carcinomas.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 1999 Nov;5(11):1317-21 [10546001.001]
  • [Cites] Science. 2008 Mar 7;319(5868):1352-5 [18323444.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36502-5 [11013229.001]
  • [Cites] Oncogene. 2000 Nov 9;19(47):5338-47 [11103935.001]
  • [Cites] Mod Pathol. 2001 Jan;14(1):20-8 [11211306.001]
  • [Cites] Nucleic Acids Res. 2001 Mar 15;29(6):1300-7 [11238996.001]
  • [Cites] Oncogene. 2001 Feb 22;20(8):962-71 [11314031.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6234-8 [11507077.001]
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):1870-9 [11682618.001]
  • [Cites] Nat Genet. 2002 Oct;32(2):306-11 [12355087.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3428-32 [12626748.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):4991-8 [12960092.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):160-8 [14722605.001]
  • [Cites] Nat Cell Biol. 2004 Feb;6(2):168-70 [14755273.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):792-804 [15459660.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):295-300 [1406933.001]
  • [Cites] Cell. 1995 May 5;81(3):323-30 [7736585.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Prog Mol Subcell Biol. 1998;20:43-71 [9928526.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):1002-7 [9927683.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5293-303 [10498881.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • [Cites] Oncogene. 2005 Jul 14;24(30):4861-6 [15897900.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2371-9 [15919720.001]
  • [Cites] Mol Biol Cell. 2005 Oct;16(10):5013-25 [16030261.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8747-53 [16204044.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):11-23 [16372018.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Oct;27(5):241-52 [16447816.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):459-71 [16766265.001]
  • [Cites] Neurosurgery. 2006 Aug;59(2):341-53; discussion 341-53 [16883174.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Apr;2(4):220-30 [16932287.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):707-16 [16954426.001]
  • [Cites] N Engl J Med. 2006 Sep 7;355(10):1037-46 [16957149.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Dec;2(12):681-93 [17143315.001]
  • [Cites] Pituitary. 2009;12(1):40-50 [18270844.001]
  • [Cites] Nature. 2006 Dec 21;444(7122):1038-43 [17183314.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19842-7 [17170138.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):749-59 [17071631.001]
  • [Cites] Endocr Rev. 2007 Apr;28(2):165-86 [17325339.001]
  • [Cites] Oncogene. 2007 Aug 16;26(38):5596-605 [17353909.001]
  • [Cites] J Biol Chem. 2007 Aug 24;282(34):24731-42 [17569660.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C1082-92 [17626243.001]
  • [Cites] Cell. 2007 Oct 19;131(2):309-23 [17956732.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10564-72 [17975001.001]
  • [Cites] Endocrinology. 2007 Dec;148(12):6019-25 [17872367.001]
  • [Cites] Cell Death Differ. 2008 Jan;15(1):202-12 [17962814.001]
  • [Cites] J Cell Sci. 2000 Oct;113 ( Pt 20):3613-22 [11017877.001]
  • (PMID = 18981426.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA075979; United States / NCI NIH HHS / CA / CA75979
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn1a protein, mouse; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / Securin; 0 / Tumor Suppressor Proteins; 0 / pituitary tumor-transforming protein 1, human; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Atm protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


65. Atallah S, Albert M, Larach S: Transanal minimally invasive surgery: a giant leap forward. Surg Endosc; 2010 Sep;24(9):2200-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the clinical application of this technique and present preliminary data that show TAMIS to be an effective tool for resection of both malignant and benign lesions of the rectum.
  • Patients with biopsy-proven malignant lesions were required to undergo endorectal ultrasound preoperatively to determine tumor stage.
  • To perform TAMIS, a single-incision laparoscopic surgery port (SILS Port, Covidien) is introduced into the anal canal by applying steady manual pressure.
  • The average distance from the anal verge was 9.3 cm and the mean tumor diameter confirmed by pathology measured 2.93 cm.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Biopsy. Endosonography. Female. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures. Neoplasm Staging. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20174935.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


66. Koebrugge B, Bosscha K, Ernst MF: Transanal endoscopic microsurgery for local excision of rectal lesions: is there a learning curve? Dig Surg; 2009;26(5):372-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Transanal endoscopic microsurgery (TEM) is a minimally invasive technique for the local resection of benign and stage T1 rectal lesions in selected patients, associated with lower morbidity and mortality rates than open surgery.
  • Median distance of the lesion from the anal verge was 7.0 cm; median operating time was 90 min.
  • Postoperative staging revealed 77 tubulovillous adenomas, 22 stage T1, 5 stage T2 and 1 stage T3 carcinomas; tumor resection was radical in 86%.
  • TEM remains the treatment of choice for benign lesions and stage T1 rectal carcinomas in selected patients.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Length of Stay. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prospective Studies. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 S. Karger AG, Basel.
  • (PMID = 19923824.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


67. Whitehouse PA, Armitage JN, Tilney HS, Simson JN: Transanal endoscopic microsurgery: local recurrence rate following resection of rectal cancer. Colorectal Dis; 2008 Feb;10(2):187-93
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Transanal endoscopic microsurgery (TEM) is a safe and effective treatment for the excision of benign rectal adenomas.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Chi-Square Distribution. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Palliative Care. Prospective Studies. Statistics, Nonparametric. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17608750.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


68. Keshari KR, Kurhanewicz J, Jeffries RE, Wilson DM, Dewar BJ, Van Criekinge M, Zierhut M, Vigneron DB, Macdonald JM: Hyperpolarized (13)C spectroscopy and an NMR-compatible bioreactor system for the investigation of real-time cellular metabolism. Magn Reson Med; 2010 Feb;63(2):322-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although this preliminary study involved immortalized cells, this combination of technologies can be extended to the real-time metabolic exploration of primary benign and cancerous cells and tissues prior to and after therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochimie. 2006 May;88(5):437-48 [16359766.001]
  • [Cites] Mol Cancer Ther. 2006 Jan;5(1):187-96 [16432178.001]
  • [Cites] Biotechnol Bioeng. 2001 Sep 20;74(6):528-38 [11494221.001]
  • [Cites] Biotechnol Bioeng. 2002 Jan 5;77(1):83-90 [11745176.001]
  • [Cites] Biochem Pharmacol. 2002 Mar 1;63(5):843-51 [11911835.001]
  • [Cites] Magn Reson Med. 2002 Sep;48(3):430-9 [12210907.001]
  • [Cites] Anal Biochem. 2003 Jan 15;312(2):228-34 [12531210.001]
  • [Cites] Anal Biochem. 2003 Feb 1;313(1):145-54 [12576070.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10158-63 [12930897.001]
  • [Cites] J Theor Biol. 2007 Feb 7;244(3):500-10 [17049564.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4359-64 [17360529.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1358-66 [17499003.001]
  • [Cites] Magn Reson Med. 2007 Jul;58(1):65-9 [17659629.001]
  • [Cites] Phytochemistry. 2007 Aug-Sep;68(16-18):2330-40 [17466349.001]
  • [Cites] Nat Med. 2007 Nov;13(11):1382-7 [17965722.001]
  • [Cites] Magn Reson Med. 2007 Dec;58(6):1099-106 [17969006.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19345-50 [18032601.001]
  • [Cites] Cell Metab. 2008 Jan;7(1):11-20 [18177721.001]
  • [Cites] Chem Res Toxicol. 2008 Feb;21(2):408-20 [18095657.001]
  • [Cites] Nature. 2008 Mar 13;452(7184):230-3 [18337823.001]
  • [Cites] Bioprocess Biosyst Eng. 2008 Apr;31(3):227-39 [18074156.001]
  • [Cites] Magn Reson Med. 2008 Jul;60(1):33-40 [18581409.001]
  • [Cites] Brain. 2008 Aug;131(Pt 8):2209-19 [18669496.001]
  • [Cites] Magn Reson Med. 2008 Sep;60(3):510-6 [18727052.001]
  • [Cites] Cell. 2008 Sep 5;134(5):703-7 [18775299.001]
  • [Cites] Nat Biotechnol. 2008 Oct;26(10):1179-86 [18820684.001]
  • [Cites] Cancer Res. 2008 Oct 15;68(20):8607-15 [18922937.001]
  • [Cites] Mol Cancer. 2008;7:79 [18939998.001]
  • [Cites] J Cell Biochem. 2003 Oct 15;90(3):525-33 [14523987.001]
  • [Cites] Acta Physiol Scand. 1974 Sep;92(1):21-6 [4370414.001]
  • [Cites] NMR Biomed. 1990 Feb;3(1):23-6 [2390450.001]
  • [Cites] Biotechnology (N Y). 1990 Dec;8(12):1282-5 [1366962.001]
  • [Cites] Biochemistry. 1992 Aug 25;31(33):7488-93 [1510935.001]
  • [Cites] NMR Biomed. 1992 Jul-Aug;5(4):185-92 [1449954.001]
  • [Cites] Magn Reson Med. 1993 Feb;29(2):244-8 [8429789.001]
  • [Cites] Am J Physiol. 1994 Jul;267(1 Pt 1):C195-203 [8048479.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2012-6 [7743493.001]
  • [Cites] Magn Reson Med. 1996 Feb;35(2):194-200 [8622583.001]
  • [Cites] J Lab Clin Med. 1996 Oct;128(4):408-16 [8833890.001]
  • [Cites] J Biol Chem. 1998 May 15;273(20):12187-94 [9575166.001]
  • [Cites] NMR Biomed. 1998 Apr;11(2):55-66 [9608589.001]
  • [Cites] Cell Biochem Funct. 2004 Nov-Dec;22(6):343-52 [15386533.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] Magn Reson Med. 2005 Jul;54(1):67-78 [15968647.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 12;333(4):1139-45 [15967408.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9369-76 [16230400.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10149-53 [16287997.001]
  • [Cites] Tissue Eng. 2006 Jul;12(7):2001-8 [16889528.001]
  • (PMID = 20099325.001).
  • [ISSN] 1522-2594
  • [Journal-full-title] Magnetic resonance in medicine
  • [ISO-abbreviation] Magn Reson Med
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES010126; United States / NIBIB NIH HHS / EB / R01 EB007588; United States / NIBIB NIH HHS / EB / R21 EB007588; United States / NIGMS NIH HHS / GM / R21 GM075941-01; United States / NIGMS NIH HHS / GM / R21 GM075941-02; United States / NIGMS NIH HHS / GM / R21 GM075941-03; United States / NIGMS NIH HHS / GM / R21 GM075941; United States / NIBIB NIH HHS / EB / R01 EB007588-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Isotopes; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS178870; NLM/ PMC2829258
  •  go-up   go-down


69. Cuschieri K, Wentzensen N: Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev; 2008 Oct;17(10):2536-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia.
  • Human papillomavirus (HPV) infection of the genital tract is very common and normally follows a benign clinical course; however, in an unfortunate minority of infected individuals, it can cause disease that sometimes leads to cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasm Proteins / genetics. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis. RNA, Messenger / analysis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Mass Screening / methods. Precancerous Conditions / diagnosis. Precancerous Conditions / genetics. Precancerous Conditions / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2006 Nov 1;107(9):2307-13 [17029280.001]
  • [Cites] Int J Cancer. 2007 Jan 15;120(2):351-6 [17066437.001]
  • [Cites] Cancer. 2006 Dec 25;108(6):494-500 [17063495.001]
  • [Cites] Cancer. 2007 Feb 25;111(1):58-66 [17186505.001]
  • [Cites] Cancer. 2007 Feb 25;111(1):1-14 [17219448.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2435-8 [17294450.001]
  • [Cites] J Low Genit Tract Dis. 2007 Apr;11(2):98-104 [17415114.001]
  • [Cites] Cancer. 2007 Apr 25;111(2):83-92 [17334990.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1419-24 [17342094.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2599-605 [17473189.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jul;26(3):223-8 [17581402.001]
  • [Cites] Dis Markers. 2007;23(4):213-27 [17627057.001]
  • [Cites] J Med Virol. 2000 Oct;62(2):251-8 [11002256.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):276-84 [11291057.001]
  • [Cites] Mol Diagn. 2001 Jun;6(2):125-30 [11468697.001]
  • [Cites] Oncogene. 2001 Nov 26;20(54):7874-87 [11753670.001]
  • [Cites] Oncogene. 2001 Nov 26;20(54):7888-98 [11753671.001]
  • [Cites] Acta Cytol. 2002 Jan-Feb;46(1):25-9 [11843554.001]
  • [Cites] Ophthalmology. 2002 Mar;109(3):542-7 [11874759.001]
  • [Cites] J Mol Diagn. 2002 May;4(2):97-102 [11986400.001]
  • [Cites] Cancer. 2002 Apr 15;94(8):2199-210 [12001118.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1948-52 [16103442.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):35-40 [15790434.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):578-84 [16139346.001]
  • [Cites] Cancer. 2005 Dec 25;105(6):461-7 [16116604.001]
  • [Cites] Int J Cancer. 2006 Mar 1;118(5):1254-60 [16161049.001]
  • [Cites] Dis Markers. 2007;23(4):273-81 [17627062.001]
  • [Cites] Dis Markers. 2007;23(4):315-30 [17627065.001]
  • [Cites] Int J Cancer. 2004 Mar 1;108(6):871-6 [14712490.001]
  • [Cites] Lancet. 2007 Sep 8;370(9590):890-907 [17826171.001]
  • [Cites] N Engl J Med. 2007 Oct 18;357(16):1579-88 [17942871.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2787-93 [17722112.001]
  • [Cites] Lancet. 2007 Nov 24;370(9601):1764-72 [17919718.001]
  • [Cites] J Clin Pathol. 2008 Jan;61(1):132-7 [17468293.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Jan;6(1):83-95 [18267061.001]
  • [Cites] Am J Surg Pathol. 2008 Apr;32(4):502-12 [18223479.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1389-99 [12409715.001]
  • [Cites] Diagn Cytopathol. 2002 Dec;27(6):365-70 [12451568.001]
  • [Cites] J Clin Pathol. 2003 Jan;56(1):56-63 [12499437.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):187-93 [12548164.001]
  • [Cites] Anal Quant Cytol Histol. 2003 Feb;25(1):8-11 [12630076.001]
  • [Cites] Cancer. 2003 Apr 25;99(2):89-96 [12704688.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):665-73 [12861062.001]
  • [Cites] EMBO J. 2003 Aug 15;22(16):4212-22 [12912919.001]
  • [Cites] Acta Cytol. 2003 Jul-Aug;47(4):616-23 [12920756.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):201-8 [14529682.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):492-6 [15006929.001]
  • [Cites] J Med Virol. 2004 May;73(1):65-70 [15042650.001]
  • [Cites] Acta Cytol. 2004 Mar-Apr;48(2):173-80 [15098536.001]
  • [Cites] Cancer. 2004 Apr 25;102(2):100-8 [15098254.001]
  • [Cites] Cancer. 2004 Jun 25;102(3):142-9 [15211472.001]
  • [Cites] J Clin Microbiol. 2004 Jul;42(7):3176-84 [15243079.001]
  • [Cites] J Med Virol. 2004 Sep;74(1):107-16 [15258976.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1355-60 [15298958.001]
  • [Cites] Diagn Cytopathol. 2004 Oct;31(4):235-42 [15452898.001]
  • [Cites] Hum Pathol. 1992 Feb;23(2):117-28 [1310950.001]
  • [Cites] J Virol Methods. 1991 Dec;35(3):305-13 [1667790.001]
  • [Cites] Int J Cancer. 1992 Jul 9;51(5):831-4 [1319412.001]
  • [Cites] Gynecol Oncol. 1995 Feb;56(2):239-44 [7896192.001]
  • [Cites] J Virol Methods. 1995 Jul;54(1):75-81 [7559859.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4350-4 [8633069.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1741-8 [9846965.001]
  • [Cites] Virchows Arch. 2004 Dec;445(6):610-5 [15378361.001]
  • [Cites] Virchows Arch. 2004 Dec;445(6):616-20 [15480761.001]
  • [Cites] Acta Cytol. 2004 Nov-Dec;48(6):771-82 [15581161.001]
  • [Cites] Diagn Cytopathol. 2005 Jan;32(1):21-4 [15584047.001]
  • [Cites] J Virol Methods. 2005 Mar;124(1-2):211-5 [15664071.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):267-73 [15492761.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):367-72 [15734959.001]
  • [Cites] Int J Cancer. 2005 May 10;114(6):973-6 [15645423.001]
  • [Cites] J Clin Pathol. 2005 May;58(5):525-34 [15858126.001]
  • [Cites] Zentralbl Gynakol. 2005 Jun;127(3):140-5 [15915391.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):908-15 [15943992.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9 [16030305.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):347-53 [16445657.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):791-6 [16287075.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):384-91 [16415792.001]
  • [Cites] Clin Sci (Lond). 2006 May;110(5):525-41 [16597322.001]
  • [Cites] J Clin Microbiol. 2006 Apr;44(4):1310-7 [16597856.001]
  • [Cites] Cancer. 2006 Apr 25;108(2):119-23 [16411180.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):1102-7 [16570279.001]
  • [Cites] Br J Dermatol. 2006 Jul;155(1):129-36 [16792764.001]
  • [Cites] J Clin Pathol. 2006 Aug;59(8):827-30 [16467166.001]
  • [Cites] J Virol Methods. 2006 Oct;137(1):58-62 [16828171.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):62-6 [16494930.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):18-20 [16919709.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1017-28 [16679355.001]
  • (PMID = 18842994.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA CP010124-14
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / P16 protein, human; 0 / RNA, Messenger
  • [Number-of-references] 89
  • [Other-IDs] NLM/ NIHMS212843; NLM/ PMC2900792
  •  go-up   go-down


70. Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA, Heinz DE, Shroyer KR, Duncan MW, Haugen BR: Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog; 2006 Aug;45(8):613-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to better understand basic mechanisms of tumor development and identify potential new biomarkers, we have performed difference gel electrophoresis (DIGE) and peptide mass fingerprinting on pooled protein extracts from patients with papillary thyroid carcinoma (PTC) compared with matched normal thyroid tissue.
  • We confirmed S100A6 as a potentially useful biomarker using immunohistochemical analysis (85% sensitivity and 69% specificity for distinguishing benign from malignant thyroid neoplasms).

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9 [11752453.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Mar;56(3):281-90 [11940037.001]
  • [Cites] Proteomics. 2002 Jun;2(6):706-12 [12112852.001]
  • [Cites] Oncogene. 2002 Aug 1;21(33):5056-68 [12140756.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1777-80 [12168868.001]
  • [Cites] Cancer. 1977 Jul;40(1):284-300 [880557.001]
  • [Cites] Endocrinologie. 1979 Oct-Dec;17(4):233-9 [392693.001]
  • [Cites] Anal Biochem. 1984 Apr;138(1):141-3 [6731838.001]
  • [Cites] J Biol Chem. 1991 Oct 25;266(30):20198-204 [1939080.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Dec;75(6):1398-400 [1464638.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):553-9 [8426623.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6027-31 [7954439.001]
  • [Cites] J Chromatogr B Biomed Appl. 1995 May 5;667(1):153-60 [7663678.001]
  • [Cites] Int J Cancer. 1996 May 16;66(4):420-6 [8635854.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3112-7 [8674069.001]
  • [Cites] Hum Pathol. 1996 Jul;27(7):633-6 [8698304.001]
  • [Cites] Cancer Res. 1996 Aug 15;56(16):3634-7 [8705997.001]
  • [Cites] Biochim Biophys Acta. 1996 Aug 23;1316(3):203-9 [8781539.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):325-32 [8903474.001]
  • [Cites] Electrophoresis. 1997 Oct;18(11):2071-7 [9420172.001]
  • [Cites] N Engl J Med. 1998 Jan 29;338(5):297-306 [9445411.001]
  • [Cites] Semin Surg Oncol. 1999 Jan-Feb;16(1):34-41 [9890738.001]
  • [Cites] Electrophoresis. 1998 Dec;19(18):3213-6 [9932817.001]
  • [Cites] Mol Endocrinol. 2005 Mar;19(3):683-97 [15528267.001]
  • [Cites] Histopathology. 2005 May;46(5):569-75 [15842639.001]
  • [Cites] Bioessays. 2002 Aug;24(8):749-57 [12210536.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):68-75 [12538453.001]
  • [Cites] Lancet. 2003 Feb 8;361(9356):501-11 [12583960.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] J Proteome Res. 2003 Mar-Apr;2(2):199-205 [12716134.001]
  • [Cites] J Clin Pathol. 2003 Jun;56(6):401-5 [12783963.001]
  • [Cites] Proteomics. 2003 Jul;3(7):1162-71 [12872217.001]
  • [Cites] Thyroid. 2003 Jul;13(7):613-20 [12964965.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):994-1005 [14764826.001]
  • [Cites] Tumori. 2003 Sep-Oct;89(5):517-9 [14870775.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Proteomics. 2004 Mar;4(3):793-811 [14997500.001]
  • [Cites] FASEB J. 2004 Mar;18(3):560-1 [14715705.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2035-43 [15041723.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1600-5 [15083192.001]
  • [Cites] J Clin Invest. 2004 Apr;113(8):1234-42 [15085203.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2898-903 [15087409.001]
  • [Cites] Mol Cell Proteomics. 2004 Jun;3(6):531-3 [15075378.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4069-77 [15205313.001]
  • [Cites] Mult Scler. 2004 Jun;10(3):245-60 [15222687.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3214-23 [15240595.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):425-36; discussion 436-7 [15319714.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1111-22 [15336958.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3531-9 [15337802.001]
  • [Cites] Proteomics. 2004 Sep;4(9):2776-88 [15352251.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Sep;89(9):4264-6 [15356019.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6586-97 [15475448.001]
  • [Cites] Mol Cell Proteomics. 2004 Oct;3(10):960-9 [15238602.001]
  • [Cites] Arch Pathol. 1967 Dec;84(6):601-14 [6054261.001]
  • [Cites] Cancer. 1971 Sep;28(3):763-74 [5096937.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Eur J Biochem. 2000 Oct;267(19):6067-73 [10998068.001]
  • [Cites] Adv Clin Path. 2000 Oct;4(4):155-8 [11436147.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):4920-5 [11600563.001]
  • [Cites] Rev Endocr Metab Disord. 2000 Apr;1(3):173-81 [11705003.001]
  • (PMID = 16788983.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA100560; United States / NCI NIH HHS / CA / P30 CA046934; United States / NCI NIH HHS / CA / R01 CA100560; United States / NCI NIH HHS / CA / P30 CA46934-15; United States / NIDDK NIH HHS / DK / R01 DK054383; United States / NIDDK NIH HHS / DK / DK054383
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Neoplasm Proteins; 0 / S100 Proteins; 105504-00-5 / S100A6 protein, human
  • [Other-IDs] NLM/ NIHMS20526; NLM/ PMC1899163
  •  go-up   go-down






Advertisement